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ABSTRACT
Given the widespread costs associated with alcohol use disorder (AUD; World Health
Organization, 2011), it is unsurprising that many treatments exist for AUD. Moreover,
many treatments have been rigorously studied via experimental research designs. In such
research, treatment success has been defined predominantly as abstinence from alcohol
or, more recently, no heavy drinking days. Consumption-based definitions of treatment
success, rather than alternative non-consumption based definitions, have dominated in the
field for at least two reasons. First, there are multiple measures of similar nonconsumption constructs (e.g., quality of life, psychosocial functioning), and very little
research has been conducted to direct researchers toward the best non-consumption
measures to use among AUD populations. Second, it is assumed that non-consumption
measures are insensitive and, therefore, consumption must be used as a surrogate measure
for more clinically meaningful non-consumption measures. The present research study
iv

empirically addressed these two barriers that have thwarted attempts to shift toward
including non-consumption variables in our definitions of treatment success. Using
secondary data analysis of data collected from the COMBINE Study (Anton et al., 2006)
and Project MATCH (Project MATCH Research Group, 1997), the present study
conducted several tests of measurement stability, reliability, validity, sensitivity, and
specificity. To test measurement stability the current study examined effect sizes and
measurement invariance across time to test if non-consumption measures may be viable
options for comparing pre- and post-treatment scores on these measures. The present
study also conducted analyses on psychometric properties of extant measures: internal
consistency reliability, construct validity, convergent validity. Finally, receiver operating
characteristic curve analyses were conducted of total scale scores, subscales, and
individual items when available and appropriate to test the sensitivity and specificity of
non-consumption measures in detecting post-treatment and 12-month outcomes. The
Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), and the brief World
Health Organization Quality of Life measure (WHOQOL-BREF) were invariant across
time and performed the best overall across all psychometric and sensitivity/specificity
analyses conducted in the present manuscript. All other measures examined in the current
study had at least some promising results, with the sole exception of the Addiction
Severity Index (ASI), which had weak findings across all analyses. Moreover, some nonconsumption measures (e.g., Drinker Inventory of Consequences, Obsessive-Compulsive
Drinking Scale) had baseline to post-treatment effect sizes as large as some consumptionbased outcome effect sizes. The results of the present study have identified gold standard
measures for assessing mental health and quality of life. Future research should use the
v

BSI, BDI, and WHOQOL-BREF to examine clinically-relevant changes beyond
consumption outcomes. The present findings also indicate that consumption measures
may not be needed to serve as surrogates for these clinically relevant constructs. These
findings represent the possibility of a paradigm shift in the field of AUD treatment
research evaluation to incorporate non-consumption outcomes.
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Introduction
Background
Alcohol misuse causes significant problems worldwide and affects the lives of
millions of people. Recent estimates suggest excessive alcohol consumption and alcoholrelated problems comprise the third highest risk for disease and disability worldwide
(World Health Organization, 2011). The prevalence of current (i.e., past twelve months)
alcohol use disorder (AUD) in the United States has been estimated recently to be 13.9%
(Grant et al., 2015). Given the prevalence of AUD and related public health concerns,
research has focused on the development and evaluation of psychosocial and
pharmacologic treatments for AUD.
Historically, success in AUD treatment trials has been defined primarily by
abstinence (binary outcome) or percentage of days abstinent (PDA, continuous outcome;
Food and Drug Administration (FDA), 2006). The FDA (2015) recently proposed percent
subjects with no heavy drinking days (PSNHDD), in addition to abstinence, as primary
endpoints for evaluating AUD treatment trials, with “no heavy drinking days” defined as
no days with 4/5 or more standard drinks for women/men (FDA, 2015). Other AUD
treatment outcome definitions that are commonly used include: number of drinks per
drinking day (DDD; e.g., Greenfield, 2000), drinks per day (DPD; e.g., Morgenstern et
al., 2007); and frequency of heavy drinking (percent heavy drinking days, PHDD; e.g.,
Anton et al., 2006). Importantly all the outcomes commonly used to define treatment
success (PDA, PSNHDD, DDD, DPD, PHDD) are consumption-based measures; thus,
treatment success is often solely defined by whether a client is still drinking and/or how
much alcohol an individual drinks.
1

Alcohol consumption, variously defined, has been the dominant outcome variable
in AUD treatment research for a number of reasons. First, consumption variables are
easily quantified using standard drinks, and a variety of consumption variables can be
examined, including dichotomous (e.g., abstinent or not) and continuous variables (e.g.,
PDA, DDD). Second, alcohol consumption is tied inherently to the development of
AUD—without consuming alcohol, it is impossible for one to develop AUD. Third, it has
been argued that alcohol consumption is likely a surrogate measure for how an individual
is functioning (FDA, 2015). However, relying upon consumption-based variables as the
sole markers of treatment success is limited in substantial ways.
Consumption-based outcome variables often fail to acknowledge the complex
processes underlying the development, maintenance, and recovery from AUD.
Recovering from addiction is more complex than simply abstaining from substance use,
and defining treatment success purely by consumption often fails to adequately portray
the complex, multifaceted recovery process (e.g., Donovan et al., 2012; Substance Abuse
and Mental Health Services Administration, 2012; Tiffany et al., 2012). Cisler and
Zweben (1999, 2003) attempted to address the need for a more complex representation of
outcomes and created a composite measure to reconcile consumption with alcohol-related
problems. This “composite clinical outcome” measure had four levels: (1) abstinence; (2)
moderate drinking (<4 drinks for females; <6 drinks for males) without problems
(drinking consequences occurred never or only once or twice); (3) heavy drinking (3+
occasions of 4+ drinks for females and 6+ drinks for males) or problems (recurrent
drinking consequences occurring 3+ times); and (4) heavy drinking with problems.
2

Despite studies validating the composite clinical outcome measure (Cisler & Zweben,
1999, 2003), this measure has never been widely adopted in the field. Recently, Kaskutas
and colleagues (2014) developed a measure to identify specific components that were
most important to how clients and their loved ones evaluated whether or not a client’s
AUD had improved. Initial item testing and factor analysis indicated clients and their
loved ones viewed a variety of non-consumption variables as important, including
functioning and consequences (Kaskutas et al., 2014). Similarly, Neale and colleagues
(2014) recently collected qualitative data to examine how treatment providers define
treatment success. Findings suggest a broad range of outcomes are meaningful to
treatment providers, including psychological and physical health, social functioning, and
well-being (Neale et al., 2014). Thus, defining treatment success solely by consumption
is an inaccurate definition of recovery from multiple clinically important perspectives.
Defining treatment success by non-consumption outcome variables may also be
more consistent with the variety of theoretical models of addiction that underlie AUD
treatment development. Various theories (e.g., cognitive theory versus behavioral theory)
posit different key outcomes (e.g., changes in thoughts versus behavior) and examining
all AUD treatments primarily by consumption (e.g., PDA, PSNHDD), regardless of
underlying theory or hypothesized mechanisms of change is inconsistent with the myriad
of addiction models. Moos and Finney (1983) criticized this inconsistency and noted that
theory should be used to guide treatment evaluation. Similarly, addictions researchers
have called for the evaluation of theory-specific outcomes in substance use treatment
research rather than a single, one-size-fit all outcome variable (Del Boca & Darkes, 2012;
Donovan et al., 2012). Further, Moos and Finney (1983) called for a greater
3

acknowledgment of the complexities associated with AUD in AUD treatment research
(i.e., AUD is not simply a phenomenon of using too much alcohol but rather one of
consequences incurred by such alcohol use). In sum, the AUD treatment research
community has recognized that AUD is complex and that research must account for such
complexities to be consistent with theory in evaluating treatment. This recognition means
moving beyond the singular approach of using consumption-based definitions of
treatment success.
Despite these arguments for shifting away from consumption as the sole index of
AUD treatment success to more clinically and theoretically useful non-consumption
measures, consumption outcomes have remained dominant in AUD treatment research.
Efforts to incorporate non-consumption outcome measures into AUD treatment research
have been stymied for at least two reasons. First, there are multiple measures of similar
non-consumption constructs (e.g., quality of life), and research is needed to direct
researchers toward the “gold standard” (i.e., psychometrically sound) measures that are
viable for use among AUD populations (e.g., Del Boca & Darkes, 2012). Second, it is
assumed that non-consumption measures are insensitive and, therefore, consumption
must be used as a “surrogate” measure for more clinically meaningful non-consumption
measures (FDA, 2015, p. 2). However, this assumption has not been subjected to
empirical testing and some research has found non-consumption measures (e.g.,
temptation) to better predict AUD treatment outcomes (quantity, frequency, and alcoholrelated problems) than consumption-based measures (Witkiewitz, 2013).
Present Study
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The present study consisted of extensive secondary data analyses to evaluate and
compare psychometric properties and the sensitivity/specificity of clinically meaningful
non-consumption outcome variables (e.g., quality of life) for evaluating AUD treatment.
To this end, the present study had two primary aims. Aim 1 was to examine the
psychometric properties of several non-consumption self-report measures in order to
explore the viability of these measures as potential “gold standard” measures to compare
pre- and post-AUD treatment changes in these constructs. Accordingly, the present study
conducted several tests of measurement stability, validity, and reliability. To test
measurement stability the current study examined effect sizes and measurement
invariance across time to test if non-consumption measures may be viable options for
comparing pre- and post-treatment scores on these measures. Construct validity was
examined via confirmatory factor analyses; convergent validity was examined via
bivariate correlations with measures hypothesized to be related. These results informed
further measure psychometric evaluation via examination of internal consistency total
scale scores and sub-scale scores upheld via CFA and invariance testing. Aim 2 was to
further test the viability of these non-consumption measures by examining total scale,
subscale, and individual item sensitivity/specificity in an incremental approach based on
CFA and invariance testing results and levels of sensitivity/specificity for each higherlevel score (i.e., individual items were only examined if subscales had adequate
sensitivity/specificity). Together, results from Aims 1 and 2 highlighted non-consumption
outcome measures that may be most appropriate for use in AUD treatment research
contexts to define treatment success in clinically meaningful ways.
Methods
5

Data
The present study used data collected from the COMBINE Study (Anton et al.,
2006) and Project MATCH (Project MATCH Research Group, 1997). Table 1
summarizes the participant demographics, design, and exclusion criteria used in these
two studies. Psychometric, measurement invariance, and sensitivity/specificity analyses
were conducted using measures that were consistent with the variables previously
identified as important by researchers, clients and their loved ones, and treatment
providers (Donovan, et al., 2012; Kaskutas et al., 2014; Neale et al., 2014) and included:
1) drinking consequences/severity, 2) mental health, 3) craving/temptation, 4) quality of
life/functioning. Table 2 details the measures used in these analyses and Figure 1
summarizes the analyses conducted. These non-consumption variables were comprised of
full-measure information (e.g., Drinker Inventory of Consequences (DrInC) total
summary score; Miller, Tonigan, & Longabaugh, 1995) as well as sub-scale data when
available (e.g., factor-analytically supported subscales of the DrInC) and individual-item
analyses where applicable (e.g., individual items of the DrInC if DrInC subscales
performed adequately).
COMBINE. COMBINE (N = 1383) was a large, multisite, randomized controlled
trial of 9 treatment combinations of psychosocial interventions (Combined Behavioral
Intervention (CBI) or Medication Management (MM)) and medication (acamprosate,
naltrexone, or placebo). Assessments were conducted at baseline (i.e., pre-treatment),
during treatment, and post-treatment follow-ups at 10-weeks (immediately post-treatment
= “week 16” post-baseline), 9-months, and 12-months. Participants were all seeking
treatment and were recruited from 11 research sites across the United States. Although
6

there were relatively few exclusion criteria (presented in Table 1: history of other
substance use disorder except cannabis, psychiatric diagnoses requiring medication,
unstable medical conditions), there were strict inclusion criteria in the COMBINE Study
(Anton et al., 2006). All eligible participants must have 1) met criteria for Alcohol
Dependence per the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV; American Psychiatric Association, 1994), 2) have had between 4 and
21 days of abstinence prior to their baseline assessment session, and 3) have consumed >
14/21 drinks per week (for women/men) with at least 2 heavy drinking days (> 4/5 drinks
for women/men) within a consecutive 30 day period in the 90 days preceding their
baseline assessment. These specific inclusion criteria resulted in greater homogeneity of
alcohol consumption and problem severity in the COMBINE Study than those in Project
MATCH. The sample homogeneity in COMBINE was intentional with the study design
since the COMBINE Study was a pharmacotherapy study and selective recruitment was
necessary to reduce medication complications.
Project MATCH. Project MATCH (N = 1726) was a large, multisite, randomized
controlled trial of psychosocial treatments (Cognitive Behavioral Therapy (CBT),
Motivational Enhancement Therapy (MET), or Twelve-Step Facilitation (TSF)).
Participants were all seeking treatment and were provided 12 weeks of treatment.
Assessments were conducted at baseline (i.e., pre-treatment), during treatment, and every
three months post-treatment for up to 12 months. Participants were recruited from 9
research sites across the United States. Participants received these treatments in either an
aftercare arm (after release from an inpatient treatment) or an outpatient treatment arm.
Participants were substantially different between these two treatment arm settings and
7

had significantly different outcomes post-treatment (Project MATCH Research Group,
1998). Sample heterogeneity in Project MATCH was deliberate in the study design
because the primary aim of MATCH was to find better treatment approaches to target
client heterogeneity. A primary difference that resulted in differences in participant
homogeneity between the COMBINE Study and Project MATCH was that Project
MATCH inclusion criteria were DSM-III-R (American Psychiatric Association, 1987)
diagnosis of alcohol abuse or dependence, whereas the COMBINE Study limited their
sample to DSM-IV diagnoses of alcohol dependence only and had additional alcohol
consumption inclusion criteria that were not paralleled in Project MATCH (Project
MATCH Research Group, 1997).
Measures
Alcohol-Related Variables. Both COMBINE and MATCH employed the Form
90 (Miller, 1996) to collect 90-day assessment window information on daily drinking
levels. From these data, multiple consumption outcome variables were computed: number
of drinks per drinking day (DDD, including only days when alcohol was consumed),
maximum number of drinks consumed in the 90-day window (MXD), drinks per day in
the assessment window (DPD, averaging across drinking and abstinent days), binary
heavy drinking (HD) data for each day, percent days abstinent (PDA), percent heavy
drinking days (PHDD), World Health Organization risk levels (WHO risk levels; WHO,
2000), and composite clinical score (abstinent, abstinent or moderate drinking without
problems, heavy drinking/problems, or heavy drinking and problems; Cisler & Zweben,
1999). WHO Risk levels included low risk (<20/40 grams of alcohol for women/men per
day), medium risk (<40/60 grams of alcohol for women/men per day), high risk
8

(<60/<100 grams of alcohol for women/men per day) or very high risk (>60/100 grams of
alcohol for women/men per day). Standard drinks were calculated using National
Institute on Alcohol Abuse and Alcoholism guidelines of 14 grams. “Heavy drinking”
was defined as 4/5 or more standard drinks for women/men (HD; NIAAA, 2004). The
composite clinical score also used information collected in COMBINE and MATCH via
the Drinker Inventory of Consequences (DrInC; Miller et al., 1995), a 45-item measure of
alcohol-related consequences (plus 5 control-scale items not included in the present study
analyses) on which higher scores indicated greater alcohol-consequence severity. The
DrInC was initially conceptualized as containing 5 consequence factors: Interpersonal,
Intrapersonal, Impulse Control, Physical, and Social Responsibility (Miller et al., 1995).
It was according to these 5-factors that an abbreviated version of the DrInC was created:
the Short Inventory of Problems (SIP; Feinn, Tennen, & Kranzler, 2003). Previously
published findings have reported sufficient internal consistency reliability as well as
convergent validity of the DrInC and the SIP in COMBINE and MATCH (α range from
0.61 to 0.87 with the DrInC generally having higher internal consistency than the SIP;
Forcehimes, Tonigan, Miller, Kenna, & Baer, 2007). Moreover, Marra and colleagues
(2014) found strict measurement invariance between Spanish and English speakers for
the SIP. However, multiple publications have proposed alternative factor structures,
including 3- and 1-factor models for the DrInC and the SIP, which may indicate
instability of previously examined factor solutions or poor construct validity of the DrInC
and SIP administrations (e.g., Alterman, Cacciola, Ivey, Habing, & Lynch, 2009; Feinn et
al., 2003; Hagman et al., 2009; Kenna et al., 2005). Of particular importance to the
current analyses, in Project MATCH the DrInC was non-uniformly administered to
9

individuals who reported 100% days of abstinence during the follow-up assessments.
Specifically, the items on the follow-up version of the DrInC are worded such that items
should be endorsed only in reference to consequences that occurred due to drinking
during the assessment window and some assessors in MATCH did not administer the
DrInC to some, but not all, of the individuals who were abstinent at follow-up. This
inconsistent administration of the DrInC in Project MATCH may have important impacts
on how well it performs psychometrically across COMBINE and MATCH.
In addition to alcohol-related consequences, alcohol dependence severity was
assessed in MATCH via the Addiction Severity Index (ASI; McLellan, Luborsky,
Woody, & O’Brien, 1980). The ASI was created with a conceptualization of having 6-7
factors: Medical Status, Employment/Social Support, Alcohol/Drug Use (sometimes
conceptualized as separate factors), Legal Status, Family/Social, and Psychiatric Status
(McLellan et al., 1992). However, other factor structures have also been published (e.g.,
Currie, El-Guebaly, Coulson, Hodings, & Mansley, 2004; Rogalski, 1987).
Administrations of the ASI have found poor to good internal consistency of each of these
factors (Currie et al., 2004) and other publications have cautioned against the use of the
ASI as a research or diagnostic instrument (DeJong, Willems, Schippers, & Hendriks,
1995). Project MATCH did not administer the full ASI that has been factor analyzed in
previous studies and only included a partial set of items.
Also included in COMBINE and MATCH were measures of alcohol
temptation/craving. In COMBINE, temptation/craving was measured by the ObsessiveCompulsive Drinking Scale (Anton, 2000). The OCDS has been widely studied and
conceptualized as a measure of alcohol craving (Anton, 2000) where higher scores
10

indicated greater alcohol craving, but various publications have found differing factor
structures (e.g., Bohn, Barton, & Barron, 1996; Connor, Jack, Feeney, & Young, 2008;
Connor, Feeney, Jack, & Young, 2010; Kranzler, Mulgrew, Modesto-Lowe, & Burleson,
1999; Roberts, Anton, Latham, & Moak, 1999). In addition to unclear construct validity
regarding differing published factor analytic results, there is mixed evidence of the
convergent validity of administrations of the OCDS (e.g., Anton, Moak, & Latham, 1996;
Connor et al., 2008; Moak, Anton, & Latham, 1998). Similarly, various administrations
of the OCDS have yielded variable internal consistency of the overall measure and its
factor analyzed subscales (e.g., Bohn et al., 1996; Kranzler et al., 1999). A slightly lessstudied measure that has been purported to measure temptation/craving is the Alcohol
Abstinence Self-Efficacy Scale (AASE; DiClemente, Carbonari, Montgomery, &
Hughes, 1994), which was administered in COMBINE and MATCH. The items in the
AASE are worded to assess temptation/craving through the confidence an individual has
in being able to avoid drinking in various circumstances. Therefore, lower AASE scores
indicated higher temptation/craving to drink. Preliminary studies have identified the
AASE as consisting of 4 factors related to situations in which individuals may be tempted
to drink: Negative Affect, Social/Positive, Physical & Other Concern, Withdrawal or
Urges (e.g., DiClemente et al., 1994; Hiller et al., 2000). Administrations of the AASE
have demonstrated strong internal consistency reliability and modest convergent validity
of total AASE score and each of the 4 subscales (DiClemente et al., 1994). In addition to
the AASE, an individual item assessing overall temptation/craving was administered in
MATCH.
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A final alcohol-related measure used in MATCH was the Alcoholics Anonymous
Involvement scale (Tonigan, Connors, & Miller 1996). The AAI assesses for attendance
of AA meetings as well as involvement with each of the 12-steps of AA. This measure
was examined in the present study as a means of examining convergent validity of items
hypothesized to be negatively or positively correlated with AA involvement.
Mental Health Variables. Mental health was assessed via multiple assessment
measures in COMBINE and MATCH. In COMBINE, mental health was assessed via the
Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983), which has been
conceptualized as assessing 9 domains of mental health as well as overall global mental
health problem severity; higher scores indicated greater mental health problem severity.
These 9 domains have been upheld via numerous factor analyses, including analyses of
the brief version of the BSI (BSI-18; e.g., Derogatis & Melisaratos, 1983; Long, Harring,
Brekke, Test, & Greenberg, 2007; Recklitis et al., 2006; Wang et al., 2010). The BSI and
BSI-18 have been administered in numerous mental health treatment studies and their
psychometric properties (internal consistency, convergent validity) have been supported
in multiple administrations of the measures.
A similarly well-studied measure of mental health is the Beck Depression
Inventory (Beck, Steer, & Brown, 1996; Beck, Steer, & Garbin, 1988), which was
administered in Project MATCH. The BDI and the second edition BDI-II measure
depression symptoms, and higher levels indicated higher depression. The BDI and BDI-II
have both been found to have either a 2- or a 3-factor structure and strong internal
consistency and convergent validity in numerous measurement administrations (e.g.,
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Arnau, Meagher, Norris, & Bramson, 2001; Beck et al., 1988; Visser, Leentjens,
Marinus, Stiggelbout, & van Hilten, 2006).
In addition to depression, mental health as a construct was also measured in
Project MATCH via a state-trait anger expression inventory: the Spielberger State-Trait
Inventory (SSTI; Forgays, Forgays, & Spielberger, 1997). Only a subset of items of the
SSTI were administered in Project MATCH. Though few studies have been published
regarding the psychometric properties of the SSTI, extant literature suggests the SSTI
items administered in Project MATCH consist of two factors: a Temperament and a
Reaction factor (Forgays et al., 1997; Kroner & Reddon, 1992; van der Ploeg, 1988).
Previous findings have also indicated administrations of the SSTI have had at least
acceptable internal consistency and convergent validity (Forgays et al., 1997; Kroner &
Reddon, 1992; van der Ploeg, 1988). The SSTI was only administered at the baseline
timepoint in MATCH.
Quality of Life/Functioning Variables. Quality of life was assessed in
COMBINE via the World Health Organization Quality of Life, brief measure
(WHOQOL-BREF; WHOQOL Group, 1998) and the Health Survey (SF-12; Ware,
Kosinski, & Keller, 1996). The WHOQOL-BREF is an abbreviated version of the 100item WHOQOL where higher scores indicate better quality of life. Previous publications
have identified the WHOQOL-BREF as comprised of a higher-order factor structure
containing 4 lower-order factors (Physical Health, Psychological Health, Social
Relationships, and Environment) and a higher-order Quality of Life factor (Skevington,
Lofty, & O’Connell, 2004). One item of the WHOQOL-BREF assessing negative affect
was erroneously omitted in administration of the WHOQOL-BREF in COMBINE.
13

Previous administrations of full version of the WHOQOL-BREF have been well-studied
and have yielded good internal consistency, convergent validity, and measurement
invariance across demographic groups (e.g., Jaracz, Kalfoss, Gorna, & Baczyk, 2006;
Skevington et al., 2004; Yao & Wu, 2005).
The SF-12 is an abbreviated version of the SF-36, and has also been widely
studied. However, unlike the WHOQOL-BREF there have been mixed findings regarding
the psychometric properties of various SF-36 and SF-12 administrations (e.g., Hann &
Reeves, 2008; Jakobsson, Westergren, Lindskov, & Hagell, 2012; Treanor & Donnelly,
2015). The SF-12 is most often conceptualized as consisting of 2 factors: Physical Health
and Psychological Health. Importantly, many of the items are “double-barreled,”
meaning that a single item asks about both physical and mental health (e.g., “...how much
of the time has your physical or emotional problems interfered with…”), which may
mean participants are responding in different ways to the same item. The double-barreled
nature of many of the SF-12 items may explain why construct validity of SF-12
administrations have been variable across studies (Miller et al., 2009). Other
psychometric properties of SF-12 administrations have been more consistently strong.
The convergent validity of the SF-12 has been supported in previous administrations
(e.g., Salyers, Bosworth, Swanson, Lamb-Pagone, & Osher, 2000) as well as the internal
consistency (e.g., Montazeri, Vahdaninia, Mousavi, & Omidvari, 2009). Both the
WHOQOL-BREF and the SF-12 are purported to measure non-disease-specific quality of
life; however, neither have been extensively examined in samples of individuals with
AUD.
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In Project MATCH, quality of life/psychosocial functioning was measured via the
Psychosocial Functioning Inventory (PFI; Feragne, Longabaugh, & Stevenson, 1983). As
described by Feragne and colleagues (1983), the PFI consists of 10 subscales and 2
composite scales and higher scores on the PFI reflect better psychosocial functioning. An
abbreviated version of the PFI was administered in Project MATCH and was coded
according to three subscales: Subjective Role Performance, Overall Social Role
Performance, and Housemate/Roommate Role (Project MATCH Research Group, 1997).
Psychometric properties of the PFI have not been well studied in either the full or
abbreviated forms.
A final metric for functioning that was used in COMBINE and MATCH consisted
of items that assessed employment status and income (ESI). These items were included in
the present study to examine convergent validity of other assessment tools. It was
hypothesized that individuals who were functioning less well would have poorer
employment status and lower income than individuals who were functioning well. Only a
single, categorical item was used for employment status in COMBINE and MATCH and
income was assessed in COMBINE but not MATCH. Further, the employment status
item had to be re-coded in COMBINE and MATCH to facilitate more meaningful
categories for analyses. Specifically, the COMBINE and MATCH employment items
were recoded to represent increasing levels of employment: unemployment or disabled =
0; homemaker, part-time employed, or retired = 1; and full-time employed = 2.
COMBINE also included one item for income that was not paralleled in MATCH (<
$15,000; $15,000 - $29,999; $30,000 - $59,000; $60,000 - $89,000; > $90,000).
Aim 1 Analyses: Psychometric Properties
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Extensive psychometric evaluation was conducted to help identify “goldstandard” measures for non-consumption outcomes. All psychometric analyses were
conducted in SPSS version 23 (IBM Corp, 2015) and Mplus version 7.3 (Muthén &
Muthén, 2012). Missing data were handled with maximum likelihood estimation,
multiple imputation, or mean-and-variance adjusted weighted least squares (WLSMV)
estimation as recommended by Kline (2011) and described in detail below. Descriptive
statistics (mean, standard deviation, frequencies) were computed in SPSS and then effect
sizes (Cohen’s d; Cohen, 1988) were calculated per Lenhard and Lenhard (2016) to
adjust for differences in sample sizes caused by attrition. A priori cutoffs for effect sizes
were: large effect sizes d > 0.8, medium effect sizes 0.8 > d > 0.2, small effect sizes d <
0.2 (Cohen, 1988).
Although work has already been done to examine various psychometric properties
of some of these measures (e.g., Forcehimes et al., 2007), some non-consumption
measures have not been evaluated in AUD-specific samples (e.g., the construct validity
of the WHOQOL-BREF) and the present analyses were more comprehensive than
previous studies. The present analyses included examinations of the following for every
non-consumption measure specified in Figure 1: effect sizes, internal consistency
reliability, convergent validity, construct validity (via confirmatory factor analyses), and
measurement invariance across time. Few studies have examined the measurement
invariance of non-consumption measures across time. Identifying measures that are
invariant over time is critical for advancing non-consumption outcome measures that may
be used to evaluate AUD treatment outcomes, assuming the changes from baseline to end
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of treatment reflect true changes in the construct of interest and not changes in the
measurement over time.
Construct Validity and Measurement invariance. In the present study, the
construct validity of non-consumption measures was examined via confirmatory factor
analysis (CFA) in the COMBINE Study and Project MATCH using baseline data to
maximize sample size. CFA analyses were guided initially by factor structures that have
been previously examined in prior studies. Data screening was conducted via SPSS
version 23 (IBM Corp, 2015) to examine potential problems with the data prior to all
analyses (e.g., nonnormality and outliers; Jackson, Gillaspy, & Purc-Stephenson, 2009).
Specifically, measures with ordered categorical response options may yield data with
rarely endorsed response categories and needed to be identified in data screening prior to
CFA analyses.
Although some have argued that factor analyses should maximize the ratio of
participants to parameters to assure model stability (e.g., Gorsuch, 1983; Streiner, 1994),
others have recommended the use of random split-half designs to test and replicate factor
structures (Floyd & Widaman, 1995). Accordingly, CFAs were conducted using
randomly split-half samples in Project MATCH and the COMBINE Study. The first half
of the sample was used to find a model with acceptable model fit (defined below); the
second half was used to replicate the model in an independent sample. Data were split
randomly via SPSS version 23 (IBM Corp, 2015). Moreover, demographic differences by
treatment site in MATCH and COMBINE were accounted for via clustering by treatment
site in all CFA and measurement invariance analyses as recommended by Heck and
Thomas (2009). Treatment site was accounted for using a sandwich estimator to calculate
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the standard errors as recommended by Muthén and Muthén (2012) for handling complex
survey data. The use of sandwich estimators to calculate standard errors is an alternative
to multilevel modeling approaches for accounting for treatment site effects in complex
survey data (Muthén & Muthén, 2012).
Hu and Bentler (1998) recommended evaluating CFA fit based on indices that
have different properties such as incremental fit and residual-based fit. In the present
study, model fit was examined via the comparative fit index (CFI), the Tucker-Lewis
Index (TLI), and the root-mean-square error of approximation (RMSEA). The CFI and
TLI are indices of incremental and relative fit whereas RMSEA is a residual-based fit
index. Several researchers have recommended the CFI as an alternative to other fit
indices such as the chi-square test of fit that are easily influenced by sample size (e.g.,
Floyd & Widaman, 1995). Marsh and colleagues (1988) recommended the TLI as a
measure of relative fit that is robust to effects of large sample sizes based on the results of
their Monte Carlo simulation study. Steiger and Lind (1980) provided justification for
using RMSEA to evaluate model fit because it has a known distribution and is robust to
problems associated with model complexity. Although some have advised against the use
of “rules of thumb” for model fit (e.g., Marsh, Hau, & Wen, 2004; Yuan, 2005), others
have argued that a priori fit indices cutoffs are important to retain objectivity in model
evaluation (Jackson et al., 2009). Accordingly, a priori cutoffs for the above fit indices
were used, as informed by Hu & Bentler (1999) and Browne & Cudeck (1993) in order to
minimize Type I and Type II error rates and reflect good model fit: CFI > 0.95; TLI >
0.95; RMSEA < 0.06. Acceptable model fit a priori cutoffs were CFI > 0.90; TLI > 0.90;
RMSEA < 0.08. Fit indices outside of these cutoffs were deemed inadequate.
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Inadequate model fit statistics in the CFAs prompted exploration of alternative
factor structures. First, individual items within each measure were examined to identify
common themes of question items. If face-valid themes were identifiable in this method,
alternative factor structures were tested using CFA and the methodology described above
regarding split-half and a priori fit cutoffs. If these models failed to provide adequate fit
or there were no easily identifiable themes across items, exploratory factor analyses
(EFA) were employed to examine alternative factor solutions. As recommended by Floyd
and Widaman (1995), EFA using principal factor analysis (PFA) was used to explore the
relationships among observed variables relative to underlying latent variables. We
anticipated non-zero correlations among the latent factors for the analyzed measures, thus
oblique rotation methods were used to allow for correlations between factors (e.g.,
geomin rotation; Floyd & Widaman, 1995).
The number of factors to be tested via CFA, based on EFA results, was
determined by parallel analysis and the scree plot. As recommended by several
publications (e.g., Floyd & Widaman, 1995; Gorsuch, 1983; Zwick & Velicer, 1986), the
elbow in the scree plot of the eigenvalues was used to indicate the number of factors. If
there were multiple points that could constitute an “elbow,” alternative factor solutions
were tested at each of these potential elbows. Notably, visual inspections of the scree plot
of EFA results have demonstrated satisfactory performance and are generally less biased
than reliance upon the Kaiser-Guttman rule of retaining all factors with eigenvalue > 1,
especially when combined with a parallel-analysis of the eigenvalues against what might
be expected by chance alone (Montanelli & Humphreys, 1976). Accordingly, scree plot
and parallel analysis guided factor enumeration for EFAs. These factor solutions were
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then tested via CFA as described above. Since items are allowed to be explained by
multiple factors in EFA, item-factor assignment was based on the factor on which the
item loaded strongest or where the item made most conceptual sense. However, if an item
failed to load > 0.40 on any factor, that item was omitted from further analyses given
research on the instability of factor solutions derived using items that load with factor
loadings < 0.40 (Guadagnoli & Velicer, 1988). When models informed thusly by EFA
results failed to provide adequate fit in CFA as defined by a priori cutoffs above, factor
analyses were ceased for that measure and invariance testing was not pursued.
When an adequately fitting factor-solution was found and replicated in
independent split-half sub-samples, measurement invariance across time was tested by
examining nested models between baseline and post-treatment datasets. Measurement
invariance over time was tested for possible non-equivalence of measurement parameters
(e.g., item intercepts, item loadings) over time (Widaman et al., 2010). Specific
procedures to test longitudinal measurement invariance followed the recommendations of
Vandenberg and Lance (2000) based on the results of their literature review. First, an
omnibus test of the equality of covariance matrices across time was tested. Next,
configural invariance was tested wherein the overall factor structure is tested as
equivalent across time (Horn & McArdle, 1992). Then, metric invariance was tested by
constraining the factor loadings to be equivalent across time (Horn & McArdle, 1992).
Next, thresholds were constrained to equality across time to establish scalar invariance
(i.e., “strong invariance”). Since Widaman and colleagues (2010) argued that strong
factorial invariance must be held across time to identify a consistent latent construct,
analyses attempted to test at least partial scalar invariance by allowing some of the
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constraints to be freed. Decisions to free constraints were based on a combination of what
made conceptual sense to free based on item question content and modification indices
(Vandenberg & Lance, 2000). Residual invariance (i.e., “strict invariance;” Widaman et
al., 2010) was not tested in the current study because all measures had categorical items
(mostly Likert-type scales) and residuals were necessarily constrained to 1 for model
identification. Thus, additional equality constraints could not be examined.
In the cases where a measure had a higher-order factor structure, analyses
followed the procedures for testing measurement invariance as specified by Chen and
colleagues (2005). In this procedure, configural invariance across time of the full model
was tested. Next, invariance of factor loadings in only the lower-order factor level was
tested. Then, invariance of factor loadings in both the lower- and higher-order factor
levels were analyzed. Once configural invariance was established, analyses included the
additional constraint of equal intercepts of the observed variables across time. Next,
analyses included the additional constraint of the intercepts of the lower-level factors to
equivalence and then constrained the disturbances of the lower-level factors to be
equivalent across time.
To determine if a more stringent level of invariance fit significantly worse than a
less stringent level of invariance (i.e., to determine the level of invariance or noninvariance), analyses used the recommendations of Widaman and colleagues (2010) and
synthesized the information provided by the fit indices (specifically, the CFI, TLI, and
RMSEA). As noted by Cheung and Rensvold (2002) among others, chi-square difference
testing is influenced by large sample sizes and may be too sensitive for measurement
invariance testing with large samples like those in COMBINE and MATCH. Thus, chi21

square difference testing was not used in the present study. Instead, measurement
invariance results were evaluated based on changes in CFI, TLI, and RMSEA or
inadequate CFI, TLI, and/or RMSEA fit indices as indicators of poorer model fit across
time (i.e., longitudinal measurement non-invariance). Many recommend against using
“rules of thumbs” for fit statistics and overall change in fit across CFI, TLI, and RMSEA
together was considered for determining measurement invariance or non-invariance (e.g.,
Vandenberg & Lance, 2000; Widaman et al., 2010). Some, however, suggest that a
change (decrease) in CFI and TLI of greater than .01 and .0.5, respectively, from one
level of invariance to another indicates the factor structure may be non-invariant (Cheung
& Rensvold, 2002). Accordingly, these rules of thumbs were considered in evaluating
change in fit statistics, but were not held as the sole determinants of non-invariance.
Reliability. Internal consistency reliability was examined via Cronbach’s alpha of
both total scale scores (e.g., DrInC summary score) and subscale scores (e.g., subscales
of the DrInC) when available and applicable (i.e., when subscales were verified via factor
analyses). Cronbach’s alpha values closer to 1 indicated better internal consistency.
Convergent Validity. Convergent validity was examined via bivariate
correlations of a given measure with measures that purport to measure similar and
opposite constructs. See Table 3 for measures that were hypothesized to possess
convergent validity (i.e., predicted significant positive or negative correlations with
conceptually similar or dissimilar constructs).
Aim 2 Analyses: Sensitivity/Specificity
Receiver Operating Characteristic (ROC) curve analyses. Secondary data
analyses of the COMBINE and MATCH data were conducted to examine the sensitivity
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and specificity of the non-consumption outcome variables using ROC curve analyses
(Hanley & McNeil, 1982). ROC curve analyses stem from signal detection theory where
“sensitivity” is the ability of a measure to detect a signal (i.e., outcome) and “specificity”
refers to the ability of a measure to discriminate between the target signal and other
signals or noise. ROC curve analyses have been used extensively in other literatures,
especially in the medical field for diagnostic testing (e.g., radiology; Hanley & McNeil,
1982). The ROC curve results were evaluated using the area under the curve (AUC)
where measures with AUC = 1 are considered perfectly sensitive/specific to detection and
discrimination of the target outcome variable and AUC < 0.50 are considered poor
(Bradley & Longstaff, 2004). Generally, AUC values > 0.65 are considered adequately
sensitive/specific (Egger & Borg, 2016). Although AUC reflects an ability to both
accurately detect and discriminate a target outcome variable, for parsimony of language,
AUC results will be described using “detection” language throughout the manuscript.
All ROC curve analyses were conducted using non-consumption outcomes
assessed at the assessment timepoint that immediately followed treatment in each study
(4-month (i.e., “week-16”) follow-up in COMBINE and 3-month follow-up in MATCH).
These analyses examined how sensitive/specific each variable is at detecting binary
outcomes at two timepoints: 4- or 3-months post-treatment and 12-months post-treatment
for: 1) abstinence versus any drinking, 2) no heavy drinking days versus any heavy
drinking days (Falk et al., 2010), 3) the World Health Organization risky drinking levels
[European Medicines Agency, 2010; with three cutoffs: (a) low risk (<20/40g alcohol for
women/men per day), (b) medium risk (<40/60g alcohol for women/men), and c) high
risk or very high risk (>41/61g alcohol for women/men; English et al., 1995); all risk
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levels were calculated via DDD, MXD, and DPD], and 4) scores on a composite clinical
outcome measure of alcohol-related problems and consumption [Cisler & Zweben, 1999;
with four cutoffs: a) abstinent, b) abstinent or moderate drinking without problems, c)
heavy drinking/problems, and d) heavy drinking and problems]. As a further test of WHO
risk levels, ROC curve analyses were also conducted for non-consumption variables’
sensitivity/specificity for changes in WHO risk level between baseline and post-treatment
(1+ and 2+ risk level changes, calculated via DDD and DPD). The results from the nonconsumption variables ROC curve analyses were compared to those of the most widely
used consumption-based measures (PDA and PHD) to understand if non-consumption
outcomes were substantially less sensitive compared to consumption outcomes. Analyses
were conducted separately in COMBINE and MATCH to examine the cross validation of
findings whenever possible.
For measures with subscale factor structures that were upheld via the CFA results,
ROC curve analyses were conducted for each subscale. When AUC > 0.65 for subscales
on at least one of the outcomes tested, individual item ROC curves were analyzed to try
to identify individual items most sensitive/specific to the evaluated outcomes. Given the
extensive number of items, we report the results from item level ROC curve analyses in
Appendix A.
Summary of Analyses
In order to synthesize the myriad results of the present study, results were distilled
and summarized using a 2-point system. Measures that had poor sensitivity/specificity,
psychometric properties, or measurement invariance were allocated 0 points; those with
mixed or modest properties were allocated 1 point. Measures with acceptable to excellent
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sensitivity/specificity, psychometric properties, or measurement invariance were
allocated 2 points. Sensitivity/specificity scores of 0 indicated area under the curve
(AUC) < 0.650 across all outcomes; 1 point indicated AUC > 0.650 and < 0.700 or mixed
results across studies or across consumption outcomes; 2 points indicated AUC > 0.700
in both COMBINE and MATCH or for most outcomes. Internal consistency reliability
scores of 0 indicated α < 0.70; 1 point indicated α > 0.70 and < 0.80 or mixed results
across studies; 2 points indicated α > 0.80 in both COMBINE and MATCH. Convergent
validity results with scores of 0 indicated non-significant (p > 0.05) or at least one
correlation in the opposite direction than was expected; 1 point indicated significant
correlations with some but not all the expected measures or mixed results across studies;
2 points indicated significant correlations in the expected direction for all measures in
both COMBINE and MATCH. Confirmatory factor analysis (CFA) results with scores of
0 indicated RMSEA > 0.08 or CFI or TLI < 0.90; 1 point indicated RMSEA < 0.08 and >
0.06 and/or CFI or TLI > 0.90 and < 0.95 or mixed results across studies; 2 points
indicated RMSEA < 0.06 and CFI or TLI > 0.95 in both COMBINE and MATCH.
Measurement invariance results with scores of 0 indicated non-invariance at the
configural level or did not proceed to invariance testing due to poor model fit; 1 point
indicated at least adequate model fit through the metric invariance testing (constraint of
the factor loadings for equivalence) or mixed results across both studies; 2 points
indicated good model fit through strong invariance testing (highest possible level of
invariance for categorical data) in both COMBINE and MATCH.
Results
Descriptive Results
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Descriptive analyses of the data are presented in Tables 4 and 5. As depicted in
Table 4, consumption outcome descriptives were largely similar between COMBINE and
MATCH datasets. The percent days abstinent (PDA) were slightly higher at all
timepoints in MATCH (baseline mean = 30.90% (SD =29.96%), N = 1725); posttreatment mean = 83.17% (SD = 28.51%), N = 1657; 12-month follow-up mean =
76.69% (SD = 33.55%), N = 1594) compared to COMBINE (baseline mean = 21.41%
(SD = 22.50%), N = 1383); post-treatment mean = 72.66% (SD = 33.49%), N = 1288;
12-month follow-up mean = 62.63% (SD = 39.12%), N = 1099). Similarly, the percent
heavy drinking days (PHDD) was higher in COMBINE (baseline mean = 70.52% (SD =
26.57%), N = 1383); post-treatment mean = 17.54% (SD = 28.69%), N = 1288; 12-month
follow-up mean = 26.20% (SD = 34.27%), N = 1171) at all timepoints compared to
MATCH (baseline mean = 63.18% (SD = 31.43%), N = 1725); post-treatment mean =
12.46% (SD = 25.09%), N = 1657; 12-month follow-up mean = 16.71% (SD = 29.17%),
N = 1594). These consumption variables were also consistent across both COMBINE and
MATCH in that the largest differences between timepoints occurred from baseline to
post-treatment and from baseline to 12-month follow-up, as evidenced by very large
effect sizes (d > 1.0) for difference from baseline and effect sizes around 0.2 in both
COMBINE (d = 0.277 for PDA and d = 0.275 for PHDD) and MATCH (d = 0.208 for
PDA and d = 0.156 for PHDD) for post-treatment to 12-month follow-up.
The pattern of change observed with consumption outcomes PDA and PHDD,
whereby the smallest changes occurred between post-treatment and 12-month follow-up
and the largest changes occurred between baseline and post-treatment and also between
baseline and 12-month follow-up, was consistent with change patterns in the non26

consumption measures (see Table 4). However, there were differences in descriptive
statistics for measures used in COMBINE versus MATCH. Similar to the different rates
of abstinence and heavy drinking days, COMBINE and MATCH differed slightly with
regards to their overall sample’s endorsement of alcohol-related consequences on the
Drinker Inventory of Consequences (DrInC) at each timepoint and for each of the 5
commonly used subscales. In COMBINE, the overall DrInC average summary score at
baseline was 47.61 (SD = 20.42; N = 1381; baseline to post-treatment d = 1.735), at posttreatment was 13.36 (SD = 18.85; N = 1098; post-treatment to 12-month d = 0.322), and
at 12-month follow-up was 19.89 (SD = 21.81; N = 965; baseline to 12-month d = 1.320).
In contrast, for MATCH the overall DrInC average summary score at baseline was 52.63
(SD = 23.32; N = 1703; baseline to post-treatment d = 0.680), at post-treatment was 35.86
(SD = 26.78; N = 985; post-treatment to 12-month d = 0.323), and at 12-month follow-up
was 27.50 (SD = 24.70; N = 789; baseline to 12-month d = 1.057). Higher DrInC scores
in Project MATCH were likely due to the different administration procedures for
COMBINE and MATCH with the DrInC, whereby the DrInC was administered to all
abstainers in COMBINE and only some of the abstainers in MATCH. Similar patterns are
observed in the commonly used subscales (physical health consequences, interpersonal
consequences, intrapersonal consequences, impulse control, and social responsibility) of
the DrInC for COMBINE and MATCH and effect sizes were generally higher in
COMBINE overall. Effect sizes differed between COMBINE and MATCH in that the
greatest changes in subscale scores occurred from baseline to post-treatment in
COMBINE whereas the largest effect sizes in MATCH occurred baseline to 12-month
follow-up. These changes may reflect the overall sample differences between COMBINE
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and MATCH and the fact that overall sample was used for descriptive analyses rather
than sub-samples (e.g., treatment arms in MATCH were not examined separately).
Other noteworthy findings from descriptive analyses were that effect sizes were
found to be very large for several of the non-consumption measures and that these effects
were on-par with those found for the primary consumption outcome variables of PDA
and PHDD. For instance, the baseline to post-treatment effect size of the ObsessiveCompulsive Drinking Scale (OCDS) in COMBINE was d = 1.762, which is larger than
the congruent effect size of the DrInC in COMBINE. Effect sizes of the Alcohol
Abstinence Self-Efficacy Scale in COMBINE and MATCH were small for the total
AASE; however, effect sizes were much larger when examining the Confidence and
Temptation subscales independently. In COMBINE, the baseline to post-treatment effect
sizes were d = 1.078 and d = 1.022 for the Confidence and Temptation subscales,
respectively. These scores were noticeably smaller in MATCH: d = 0.469 and d = 0.674,
respectively. The remaining measures had smaller effect sizes, although many effect sizes
were still notable and were in the medium range (0.2 < d < 0.8; Cohen, 1988).
Importantly, analysis of the descriptive statistics highlighted differences between
COMBINE and MATCH that may reflect the overall sample differences between
COMBINE and MATCH and the fact that overall sample was used for descriptive
analyses rather than sub-samples (e.g., treatment arm).
Descriptive analyses also indicated the potential for problems with factor analyses
given large standard deviations in some of the measures. Most notably, the Addiction
Severity Index yielded very large standard deviations, especially for the family history
(mean = 2.65, SD = 48.04, N = 1726) and legal status (mean = 141.90, SD = 384.71, N =
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1726) subscales. Moreover, since the Psychiatric status mean scores were < 1 at all three
timepoints at which this subscale was uniquely administered, descriptive analyses
suggested combining psychiatric, family history, and legal status questions into one ASI
summary score may be problematic given the range in responses possible for each
subscale. These descriptive statistics and effect sizes provide a potentially useful
overview of the performances of each measure in COMBINE and MATCH.
Descriptive results not presented in Table 4 are those for employment status and
income (ESI) items used in COMBINE and MATCH. Employment status descriptives
were: unemployment or disabled = 0 (n = 225 in COMBINE, 478 in MATCH),
homemaker, part-time employed, or retired = 1 (n = 253 in COMBINE, 282 in MATCH),
full-time employed = 2 (n = 838 in COMBINE, 847 in MATCH). COMBINE also
included one item for income that was not paralleled in MATCH (< $15,000, n = 139;
$15,000 - $29,999, n = 219; $30,000 - $59,000, n = 408; $60,000 - $89,000, n = 266; >
$90,000, n = 330). These items indicate fairly even distribution of responses and again
highlight important demographic differences between COMBINE and MATCH.
A final descriptive overview of the variables examined in the present study is
provided by Table 5, which depicts the frequencies of the binary consumption outcome
variables that were examined in the Receiver Operating Characteristic (ROC) curve
analyses. Although base rate is mathematically unrelated to sensitivity and specificity
(Pepe, 2003), the rates of each consumption outcome are interesting to consider in
comparison to one another. Perhaps most notably, the rates of each of the World Health
Organization Risk levels vary depending on how the risk levels were calculated (i.e., via
Drinks per Drinking Day (DDD), Maximum number of drinks consumed in the 90-day
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window (MXD), or via drinks per day in the assessment window (averaged across
drinking and abstinent days; DPD)). For instance, the number of participants categorized
as moderate or lower risk in COMBINE at post-treatment was: n=744, n=647, or n=1089
depending on if that risk level was calculated via DDD, MXD, or DPD, respectively.
Summary of Analyses
The overall results from the core analyses of the present study are depicted in
Table 6 and highlight that no measure performed excellently across all examined
domains. The Brief Symptom Inventory and Beck Depression Inventory performed best,
with 2 points allocated for all examined properties except sensitivity/specificity, for
which only 1 point was allocated due to mixed results. Similarly, the WHOQOL-BREF
performed well and had 2 points allocated for all except CFA results, which fit
adequately, and sensitivity/specificity, which were unable to be compared to other
measures since WHOQOL-BREF administration occurred after the post-treatment
timepoint in COMBINE. The remaining measures all had at least some promising
qualities and are described below in order of how well they performed (best performance
to poorest performance). The only measure examined in the present study that received 0
points for “poor” properties across all analyses was the Addiction Severity Index. These
results were consistent with the fact that the full ASI was not used in MATCH and, more
importantly, that the measure may be most helpful as an inventory of historical events
(e.g., number of times incarcerated for various offenses, number of family members with
histories of alcohol problems) rather than a measure that may hold utility for comparing
scores pre- and post-treatment.
Strongest Results
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Brief Symptom Inventory. The Brief Symptom Inventory was originally
conceptualized as containing 9-factors with higher scores indicating more severe
psychological symptoms: Somatization, Obsessive-Compulsive, Depression,
Interpersonal Sensitivity, Hostility, Anxiety, Psychoticism, Phobic Anxiety, and Paranoid
Ideation (Derogatis & Melisaratos, 1983). This 9-factor structure was upheld in the
COMBINE study via CFA (replication half fit indices: RMSEA = 0.022 (90% CI: 0.019,
0.025); CFI = 0.975; TLI = 0.974; presented in Table 7). Moreover, this factor structure
was invariant across time between baseline and post-treatment (week 16) timepoints in
COMBINE. The configural model of invariance testing fit very well (RMSEA = 0.011
(90% CI: 0.010, 0.012); CFI = 0.981; TLI = 0.980), as did tests of metric invariance
(RMSEA = 0.011 (90% CI: 0.009, 0.012); CFI = 0.982; TLI = 0.981), and strong
invariance (RMSEA = 0.012 (90% CI: 0.011, 0.013); CFI = 0.977; TLI = 0.977).
Moreover, as presented in Table 8, internal consistency reliability of the BSI and 9 factor
subscales varied from good to excellent, with the sole exception of the Interpersonal
Sensitivity subscale: total BSI α = 0.965, Somatization subscale α = 0.798, ObsessiveCompulsive subscale α = 0.862, Depression subscale α = 0.882, Interpersonal Sensitivity
subscale α = 0.643, Hostility subscale α = 0.790, Anxiety subscale α = 0.824,
Psychoticism subscale α = 0.864, Phobic Anxiety subscale α = 0.786, and Paranoid
Ideation subscale α = 0.836. The BSI also had good convergent validity and all bivariate
correlations were significant (p < 0.01) in the direction predicted. Specifically, the BSI
was significantly, negatively correlated with quality of life (WHOQOL-BREF: r = 0.698, p < 0.001; SF-12: r = -0.688, p < 0.001), recoded employment status (ESI
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employment item: r = -0.189, p < 0.001), and income (ESI income item: r = -0.211, p <
0.01).
The BSI also had modest sensitivity/specificity, as indicated by ROC curve
results, as detailed in Table 9. The post-treatment BSI total summary score adequately
detected 9 of 15 post-treatment consumption outcomes (AUC > 0.650), however only
detected 1 of 11 12-month follow-up consumption outcomes (AUC > 0.650). The total
BSI summary score had the highest AUC when detecting post-treatment composite
clinical outcome of heavy or lower risk (AUC = 0.833) and had the lowest AUC when
detecting 2+ level change in WHO risk level since baseline (calculated via drinks per
drinking day (DDD); AUC = 0.511). For 12-month follow-up consumption outcomes, the
BSI total score had the highest AUC when detecting the composite clinical outcome of
heavy or lower risk (AUC = 0.708) and the lowest AUC when detecting 12-month
abstinence (AUC = 0.545).
All post-treatment BSI subscales, representing the 9 factors of the BSI, adequately
detected at least 1 of 15 post-treatment consumption outcomes. The Depression factor
adequately detected 8 out of 15 post-treatment outcomes and 1 of 11 12-month follow-up
outcomes. The Interpersonal Sensitivity factor adequately detected 8 out of 15 posttreatment outcomes but 0 of 11 12-month follow-up outcomes. The Anxiety factor
adequately detected 7 out of 15 post-treatment outcomes and 1 of 11 12-month follow-up
outcomes. The Obsessive-Compulsive factor adequately detected 5 of 15 post-treatment
outcomes and 1 of 11 12-month follow-up outcomes. The Psychoticism factor adequately
detected 4 of 15 post-treatment outcomes and 1 of 11 12-month follow-up outcomes. The
Somatization factor adequately detected 4 of 15 post-treatment outcomes but 0 of 11 1232

month follow-up outcomes (AUC’s > 0.650). The Hostility factor adequately detected 3
of 15 post-treatment outcomes and 1 of 11 12-month follow-up outcomes. The Paranoia
symptom subscale adequately detected 1 of 15 post-treatment outcomes and 1 of 11 12month follow-up outcomes. Finally, the Phobic Anxiety factor adequately detected only 1
of 15 post-treatment outcomes and none of the 12-month follow-up outcomes. Every BSI
subscale had the highest AUC when detecting post-treatment and 12-month follow-up
composite clinical outcome of heavy or lower risk (AUC’s = 0.713 to 0.833 posttreatment; AUC’s = 0.638 to 0.706 12-month follow-up). Further, six of the nine
subscales had the lowest AUC’s when detecting 1+ level change in WHO risk level since
baseline (calculated via drinks per day (DPD); AUC’s = 0.529 to 0.568). For 12-month
outcomes, eight of the nine subscales had the lowest AUC’s when detecting abstinence
(AUC’s = 0.508 to 0.557); only the Psychoticism symptoms subscale had the lowest
AUC when detecting 12-month WHO risk level of moderate or lower (calculated via
drinks per drinking day (DDD); AUC = 0.523). As reported in Appendix A, many of the
items on the BSI yielded AUC’s > 0.650 at post-treatment and the 12-month follow-up.
Beck Depression Inventory. The majority of published studies report that the
BDI is comprised of 2 or 3 factors; therefore, it was unsurprising that both 2- and 3-factor
models fit well in the MATCH data (2-factor model: RMSEA = 0.030 (90% CI: 0.0250.035); CFI = 0.978; TLI = 0.975; 3-factor model: RMSEA = 0.027 (90% CI: 0.0210.032); CFI = 0.982; TLI = 0.980). Further, both the 2- and the 3-factor models sustained
comparable levels of fit through strong invariance testing between baseline and posttreatment timepoints. The 2-factor model yielded good fit through constraints of
thresholds to equivalence between timepoints (RMSEA = 0.019 (90% CI: 0.017-0.021);
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CFI = 0.968; TLI = 0.969) as did the 3-factor model (RMSEA = 0.019 (90% CI: 0.0170.021); CFI = 0.970; TLI = 0.971; see Table 7). Similarly, internal consistency was good
for the overall BDI (α = 0.889) as well as each factor, with the sole exception of the
Somatic factor in the 3-factor model (see Table 8): 2-factor Cognitive-Affective factor α
= 0.848, 2-factor Somatic factor α = 0.771, 3-factor Negative Attitudes factor α = 0.859,
3-factor Performance Impairment factor α = 0.739, 3-factor Somatic factor α = 0.478.
The convergent validity results for the total BDI were also good; the BDI was
significantly negatively correlated with psychosocial functioning (PFI; r = -0.380, p <
0.001) and employment status (ESI employment item; r = -0.150, p < 0.001).
As detailed in Table 10, ROC curve analyses indicated the BDI more strongly
detected 12-month follow-up outcomes (4 of 11 outcomes were detected at AUC > 0.650)
than post-treatment outcomes (2 of 15 outcomes were detected at AUC > 0.650). The
total BDI summary score was had the highest AUC values detecting post-treatment and
12-month composite clinical outcome of heavy or lower risk (AUC = 0.658; AUC =
0.681) and the lowest AUCs when detecting 2+ change in WHO risk level since baseline
(computed via DPD; AUC = 0.555) and 12-month abstinence (AUC = 0.596). The same
patterns were observed for all factors upheld via CFA and invariance testing (2-factor
Cognitive-Affective factor, 2-factor Somatic factor; 3-factor Negative Attitudes factor, 3factor Performance Impairment factor, 3-factor Somatic factor). For the 2-factor solution,
the Cognitive-Affective factor and Somatic factor each adequately detected 3 of 15 posttreatment outcomes, and 0 of 11 12-month outcomes. The 3-factor solution, the Negative
Affect factor adequately detected 8 of 15 post-treatment outcomes and 0 of 11 12-month
follow-up outcomes; the Performance Impairment factor and the Somatic factor each
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adequately detected 2 of 15 post-treatment outcomes and 0 of 11 12-month follow-up
outcomes. As reported in Appendix A, many of the items on the BDI yielded AUC’s >
0.650 at post-treatment and the 12-month follow-up.
World Health Organization Quality of Life. The WHOQOL-BREF has been
found to have a higher-order factor structure in previous publications (Skevington et al.,
2004). Although one item was omitted from the COMBINE Study administration, this
higher-order factor structure was acceptably upheld in COMBINE via CFA (replication
half fit indices: RMSEA = 0.050 (90% CI: 0.045, 0.055); CFI = 0.942; TLI = 0.932).
Although other factor structures have been published in other datasets (e.g., Yao & Wu,
2005), several previously published factor structures were tested in COMBINE with no
one factor structure fitting substantially better than others. Accordingly, invariance
testing was continued with the most widely-cited factor structure that made the most
conceptual sense: the higher-order factor structure described by Skevington et al. (2004).
Higher-order factor invariance testing was completed as described above with very little
change to any of the fit indices. The least constrained level of invariance testing fit
acceptably well across baseline and week 26 timepoints (RMSEA = 0.037 (90% CI:
0.035, 0.038); CFI = 0.921; TLI = 0.916) as did the highest level of constraints possible
for this measure (strong invariance: RMSEA = 0.037 (90% CI: 0.036, 0.039); CFI =
0.926; TLI = 0.930). Further, the overall WHOQOL-BREF as well as the subscale factors
had good to excellent internal consistency reliability, as indicated in Table 8 (α = 0.901
for the overall measure; Physical Health α = 0.798, Psychological Health α = 0.770,
Social Relationships α = 0.718, Environment α = 0.812). Similarly, the WHOQOL-BREF
had good convergent validity and was significantly (p’s < 0.001), negatively correlated to
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both alcohol-related consequences (DrInC; r = -0.456) and psychological symptoms
(BSI; r = -0.698) as hypothesized.
Although not accounted for in the overall results summary (Table 6) because
WHOQOL-BREF data were collected after the week 16 post-treatment timepoint, ROC
curve analyses indicated that the week 26 WHOQOL-BREF data were adequately able to
detect 12-month follow-up consumption outcomes (presented in Table 11). The total
WHOQOL-BREF score adequately detected 4 of 11 consumption outcomes. The total
WHOQOL-BREF summary score had the highest AUC when detecting 12-month
composite clinical outcome of heavy or lower risk (AUC = 0.715) and had the lowest
AUC when detecting 12-month abstinence (AUC = 0.508). The same pattern was
observed for each of the 4 subscales of the WHOQOL-BREF that were upheld via CFA
and invariance testing: 12-month composite clinical outcome of heavy or lower risk was
the outcome with the highest AUC and 12-month abstinence was the outcome with the
lowest AUC. The Physical Health, Social, and Environment subscales each only
adequately detected 12-month composite clinical outcome of heavy or lower risk (AUC’s
= 0.698, 0.691, 0.653). However, the Psychological Health subscale adequately detected
12-month WHO risk moderate or lower risk (calculated via DDD and DPD; AUC’s =
0.652, 0.659), 12-month composite clinical outcome of moderate or lower risk (AUC =
0.665), and 12-month composite clinical outcome of heavy or lower risk (AUC = 0.704).
As reported in Appendix A, several individual items of the WHOQOL-BREF adequately
detected 12-month outcomes.
Measures with Mixed Results
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Obsessive-Compulsive Drinking Scale. The Obsessive-Compulsive Drinking
Scale (OCDS) has been conceptualized as a measure of alcohol craving, but publications
have differed in their conceptualizations of factors comprising the OCDS.
Unsurprisingly, multiple steps were taken to test various factor models. First, a 2-factor
solution was tested based on the original conceptualization of the OCDS, which has been
replicated in other studies (Ansseau et al., 2000; Anton 2000; Cordero, Solis, Cordero,
Torruco, & Cruz-Fuentes, 2009). However, model fit was poor in the COMBINE data,
and the model was not tested in the replication half of the sample (RMSEA = 0.109 (90%
CI: 0.102-0.117); CFI = 0.852; TLI = 0.823). Model fit was similarly poor for alternative
2-, 3-, and 4-factor models that were based on other published findings (see Table 7).
Consequently, EFA was combined with conceptual interpretation of the items to generate
a new 4-factor model that differs slightly from other studies. These 4-factors are
consistent with a conceptualization of the OCDS as measuring: frequency of craving
thoughts (“Factor 1”), craving interference with activities (“Factor 2”), distress of the
craving (“Factor 3”), and controllability of craving (“Factor 4”). Notably, the two items
of the OCDS that assess for alcohol consumption directly were omitted from the final
factor model due to their poor contribution to the factor structures tested and per previous
findings (Anton, 2000). This 4-factor model provided acceptable fit to baseline data in
COMBINE (replication half sample: RMSEA = 0.072 (90% CI: 0.062-0.082); CFI =
0.968; TLI = 0.596). Measurement invariance testing of this new 4-factor model yielded
adequate fit statistics through strong invariance (see Table 7; RMSEA = 0.076 (90% CI:
0.062, 0.082); CFI = 0.910; TLI = 0.912). However, fit substantially worsened between
metric and strong invariance (i.e., when adding the constraint of equality of thresholds),
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which may reflect measurement non-invariance at the threshold level. Attempts to
establish partial strong invariance were unsuccessful and yielded consistently inadequate
model fit.
Despite the potential non-invariance of the OCDS at the strong invariance level,
the OCDS did have other psychometric strengths in COMBINE. The internal consistency
was strong for the total OCDS score (α = 0.852) and convergent validity results yielded
significant bivariate correlations in all Form 90 consumption variables, as predicted: PDA
(r = -0.103, p < 0.001), PHDD (r = 0.202, p < 0.001), change in WHO risk level since
baseline (as calculated with DDD: (r = 0.288, p < 0.001)), DPD (r = 0.305, p < 0.001),
DDD (r = 0.360, p < 0.001 and MXD (r = 0.320, p < 0.001).
Moreover, the total summary score of the OCDS strongly detected all posttreatment and 12-month follow-up consumption outcomes (presented in Table 12). Area
under the curve (AUC) values for detecting post-treatment outcomes ranged from 0.686
to 0.934; those for 12-month outcomes ranged from 0.690 and 0.756. For post-treatment
outcomes, the OCDS total summary score yielded the highest AUC for post-treatment
composite clinical outcome of heavy or lower risk and was lowest AUC for 1+ level
change in WHO risk level since baseline (computed via DDD). For 12-month follow-up
outcomes, the OCDS total summary score yielded highest AUC for composite clinical
outcome of moderate or lower risk and lowest AUC for WHO moderate or lower risk
(calculated via DDD).
The 4 factors that were partially supported per adequate CFA results and partial
invariance testing yielded several promising ROC curve results (AUC’s > 0.650). Factors
1 and 2 both adequately detected 11 of 15 post-treatment outcomes (all but 1+ and 2+
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risk level changes in WHO risk levels since baseline as computed via DDD and DPD):
AUC’s ranged from 0.589 to 0.782 for Factor 1 and 0.614 to 0.871 for Factor 2. Factors 1
and 2 also adequately detected 12-month composite clinical outcome of heavy or lower
risk (AUC’s = 0.668 and 0.672) and had lowest AUCs when detecting 12-month
abstinence (AUC’s = 0.604 and 0.566). Factors 3 and 4 performed even better than
Factors 1 and 2. Factor 3 adequately detected 13 out of 15 post-treatment outcomes;
AUC’s ranged between 0.631 (2+ change in WHO risk level since baseline, calculated
via DPD) and 0.877 (composite clinical outcome of heavy or lower risk). Factor 3 also
adequately detected 7 of 11 12-month outcomes; AUC’s ranged from 0.641 (WHO
moderate or lower risk, calculated via max drinks (MXD) to 0.716 (composite clinical
outcome of heavy or lower risk). Factor 4 performed superior and adequately detected 15
of 15 and 11 of 11 post-treatment (AUC’s ranged from 0.676 to 0.912) and 12-month
outcomes (AUC’s ranged from 0.682 to 0.742). For post-treatment outcomes, Factor 4
had highest AUC for composite clinical outcome of heavy or lower risk and lowest AUC
for 1+ change in WHO risk level since baseline (as calculated via DDD). For 12-month
follow-up outcomes, Factor 4 had highest AUC for composite clinical outcome of
moderate or lower risk and lowest AUC for WHO moderate or lower risk level
(calculated via DDD). As reported in Appendix A, many of the items on the OCDS
yielded AUC’s > 0.650 at post-treatment and the 12-month follow-up.
Drinker Inventory of Consequences. Similar to the OCDS, the factor structure
of the DrInC has been explored in numerous prior studies, including several publications
on the 15-item abbreviated version, the Short Inventory of Problems (SIP; e.g.,
Forcehimes, Tonigan, Miller, Kenna, & Baer, 2007; Kiluk, Dreifuss, Weiss,
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Morgenstern, & Carroll, 2012). Accordingly, a number of factor structures were tested in
COMBINE and MATCH via CFA for the DrInC as well as the SIP (see Table 7 for fit
statistics). The only factor structure tested in the present study that yielded adequate fit in
both COMBINE and MATCH and was invariant beyond configural invariance was a 3factor solution created in the present study based on a conceptualization of the DrInC as
consisting of alcohol related consequences that occur at different frequencies (e.g.,
consequences that occur commonly, such as hangovers; consequences that occur
moderately commonly; and rare consequences). As detailed in Table 7, this 3-factor
solution fit adequately at baseline in both COMBINE and MATCH (COMBINE:
RMSEA = 0.041 (90% CI: 0.038, 0.043); CFI = 0.920; TLI = 0.916; MATCH: RMSEA
= 0.040 (90% CI: 0.038, 0.042); CFI = 0.908; TLI = 0.904) and fit improved as additional
constraints were added through constraining thresholds to equivalence across time
(COMBINE: RMSEA = 0.024 (90% CI: 0.023, 0.025); CFI = 0.951; TLI = 0.952;
MATCH: RMSEA = 0.018 (90% CI: 0.017, 0.019); CFI = 0.941; TLI = 0.942).
Similarly, the total DrInC and the 3 factors all had strong internal consistency in
COMBINE and MATCH. As described in Table 8, total DrInC in COMBINE and
MATCH had α = 0.937 and α = 0.938, respectively. The 3-factor subscales in COMBINE
and MATCH were: Common Consequences α = 0.855, α = 0.833; Moderately Common
Consequences α = 0.905, α = 0.905; and Rare Consequences α = 0.808, α = 0.830.
Bivariate correlations were significant and in the expected direction for Form 90
variables (p < .01 in both COMBINE and MATCH). Other variables were also
significantly correlated in the hypothesized directions in COMBINE: OCDS r = 0.519 (p
< 0.001), AASE r = 0.153 (p < 0.001), WHOQOL-BREF r = -0.456 (p < 0.001), SF-12 r
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= -0.486 (p < 0.001), recoded employment status r = -0.225 (p < 0.001) and income r = 0.233 (p < 0.001). In MATCH, the DrInC also significantly correlated with other
hypothesized measures as predicted: PFI r = -0.479 (p < 0.001) and recoded employment
status r = -0.164 (p < 0.001). However, the DrInC had poor convergent validity in
MATCH with temptation to drink (r = -0.060, p < 0.05) and AA involvement (AAI; r =
0.336, p < .001). These inconsistent psychometrics across COMBINE and MATCH may
be due to the inconsistent administration in MATCH to individuals who had been 100%
abstinent during the follow-up window.
For the DrInC summary ROC curve analyses, all DrInC summary AUC values >
0.650 in COMBINE for both timepoints (post-treatment AUC’s = 0.677-0.944; 12-month
follow-up AUC’s = 0.684-0.736; see Table 13). Further, the first two factors adequately
detected all post-treatment and 12-month follow-up outcomes: Common Consequence
Factor post-treatment AUC’s = 0.677-0.939, 12-month AUC’s = 0.671-0.719;
Moderately Common Consequences Factor post-treatment AUC’s = 0.663-0.939, 12month AUC’s = 0.659-0.715. The Rare Consequences Factor adequately detected 14 of
15 post-treatment outcomes (AUC’s = 0.642-0.917) and 10 of 11 12-month AUC’s =
0.645-0.699). The DrInC total score and each of the 3 factors had the highest AUC’s for
composite clinical outcome of heavy or lower risk and the lowest AUC’s for 2+ level
change in WHO risk level since baseline (computed via DPD). For 12-month follow-up
outcomes, DrInC total score and each of the 3 factors all had the highest AUC’s for
composite clinical outcome of moderate or lower risk and the lowest AUC’s for
abstinence. As reported in Appendix A, many of the items on the DrInC yielded AUC’s >
0.650 at post-treatment and the 12-month follow-up.
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In MATCH, the total DrInC summary adequately detected 9 of 15 post-treatment
outcomes (AUC’s = 0.493-0.886) but failed to adequately detect any 12-month outcomes
(AUC’s = 0.424-0.590; see Table 14). Similarly, each of the 3-factors adequately
detected 8 of 15 post-treatment outcomes but failed to detect any 12-month follow-up
outcomes: Common Consequence Factor post-treatment outcomes AUC’s = 0.508-0.850;
Moderately Common Consequences Factor post-treatment outcomes AUC’s = 0.4950.879; Rare Consequences Factor post-treatment outcomes AUC’s = 0.513-0.876. Similar
with the COMBINE study results, the DrInC total score and each of the 3 factors all had
the highest AUC’s for composite clinical outcome of moderate or lower risk and the
lowest AUC’s for 2+ level change in WHO risk level since baseline (computed via DPD).
For 12-month follow-up outcomes, DrInC total score and each of the 3 factors all had the
highest AUC’s for composite clinical outcome of moderate or lower risk and the lowest
AUC’s for abstinence. As reported in Appendix A, many of the items on the DrInC
yielded AUC’s > 0.650 at post-treatment and the 12-month follow-up in Project
MATCH.
Measures with Poorer Results
Spielberger State-Trait Inventory. The two factors (Temperament and
Reaction) that have been previously described in the literature (Forgays et al., 1997)
provided poor fit to the data in Project MATCH via CFA (split half 1 sample: RMSEA =
0.116 (90% CI: 0.109-0.122); CFI – 0.902; TLI = 0.884). However, Forgays and
colleagues (1997) also described the SSTI in terms of 7 subscales. The items
administered in MATCH consisted of 4 of those 7 subscales; this 4-factor model
provided excellent fit via CFA in MATCH data (replication half sample: RMSEA =
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0.056 (90% CI: 0.048-0.064); CFI – 0.976; TLI = 0.969). Because the SSTI was only
administered at baseline in Project MATCH, measurement invariance across time was not
tested in the present study for this 4-factor solution. Factor analysis results are detailed in
Table 7. Further, the overall SSTI scale had excellent internal consistency (α = 0.887) and
all but one of these 4 factors had good internal consistency: “Factor 1” α = 0.746, “Factor
2” α = 0.865, “Factor 4” α = 0.496, and “Factor 6” α = 0.781 (as detailed in Table 8).
The SSTI performed inadequately in terms of both convergent validity and
sensitivity/specificity. The SSTI was significantly correlated with the PFI as
hypothesized (r = -0.200; p < 0.001) and the SSTI summary score using only the items in
the CFA (r = -0.053, p < 0.05) but the full SSTI summary score was not significantly
correlated with recoded employment status in MATCH (r = -0.051, p > 0.05). A bigger
weakness of the SSTI was its poor sensitivity and specificity for detecting consumption
outcomes. For the full SSTI and each of the 4 factors tested via CFA, AUC values were
below the 0.650 cutoff for all consumption outcomes at both post-treatment and 12month follow-up (see Table 15). The total SSTI score (including all items administered in
MATCH) had AUC values ranging from 0.503-0.577 and 0.499-0.559 for post-treatment
and 12-month follow-up outcomes. Similarly, AUC values for the total SSTI score
(including only the items from CFA) ranged from 0.504-0.575 and 0.501-0.561 for posttreatment and 12-month follow-up outcomes. Both of these forms of the total SSTI score
had highest AUC for post-treatment WHO moderate or lower risk (calculated via DPD)
and 12-month composite clinical outcome of heavy or lower risk; the lowest AUC’s for
both total SSTI scores were detecting 2+ level change in WHO risk level since baseline
(calculated via DPD) and 12-month abstinence. No consistent pattern emerged for which
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post-treatment and 12-month follow-up outcomes had consistently the highest or lowest
AUC for the 4 factors that were upheld via CFA, but none of the 4 factors were able to
adequately detect post-treatment or 12-month follow-up outcomes (AUC’s = 0.4900.576).
Health Survey (SF-12). The SF-12 yielded mixed and modest findings for
construct validity, measurement invariance testing, and ROC curve analyses results but
had promising internal consistency and convergent validity in COMBINE. Despite the
substantial body of literature and conceptual sense supporting the SF-12 as comprised of
2 factors (Physical Health and Psychological Health), CFA analyses indicated only an
adequate fit of this model (RMSEA = 0.080 (90% CI: 0.071, 0.090); CFI = 0.951; TLI =
0.939). Further, configural invariance was not upheld per fit indices that were outside a
priori cutoff values and the configural invariance mode fit substantially poorer than the
baseline CFA (RMSEA = 0.075 (90% CI: 0.072, 0.078); CFI = 0.854; TLI = 0.839).
Additional levels of invariance were not tested per the above evidence of configural noninvariance.
The SF-12 as administered in COMBINE had good internal consistency and
convergent validity. Internal consistency was good for total SF-12 (α = 0.874) as well as
both Physical (α = 0.805) and Psychological Health (α = 0.861) factors. Convergent
validity was particularly strong. The total SF-12 score was highly, negatively correlated
with both alcohol-related consequences (DrInC; r = -0.486, p < 0.001) and total
psychiatry symptom severity (BSI; r = -0.688, p < 0.001).
ROC curve analyses results were mixed, as detailed in Table 16. The total SF-12
summary score performed well for detecting consumption outcomes at post-treatment (8
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of 15 outcomes were adequately detected, AUC’s = 0.577-0.836), performed poorly at
detecting 12-month follow-up consumption outcomes (1 of 11 outcomes was adequately
detected, AUC’s = 0.548-0.681). Similarly, the Physical Health and Psychological Health
factors detected post-treatment consumption outcomes fairly well (4 of 15 and 9 of 15,
respectively; AUC’s = 0.522-0.766 and 0.600-0.840) whereas the Physical Health factor
failed to adequately detect any 12-month follow-up consumption outcomes (AUC’s =
0.518-0.627) and the Psychological Health factor only adequately detected 1 of 11
consumption outcomes for the 12-month follow-up (AUC’s = 0.561-0.693). The total
summary score and each of the 2 factors all had highest AUC’s for post-treatment and
12-month follow-up composite clinical outcome of heavy or lower risk. The total SF-12
score and the Physical Health factor both had lowest AUC’s for 1+ level change in WHO
risk level since baseline (calculated via DPD); the Psychological Health factor had lowest
AUC for 2+ level change in WHO risk level since baseline (calculated via DPD). The 12month abstinence was the lowest AUC for total SF-12 and both factors. As reported in
Appendix A, many of the items on the SF-12 yielded AUC’s > 0.650 at post-treatment.
Only one item on the SF-12 (item 6A: “felt calm or peaceful”) yielded AUC’s > 0.650 in
predicting the composite clinical outcome of heavy or lower risk at the 12-month followup.
Psychosocial Functioning Inventory. The items of the PFI administered in
MATCH are consistent with three of the factors in the original conceptualization of the
PFI’s construction (Feragne et al., 1983). Those three factors are: Subjective Role
Performance, Overall Social Role Performance, and Housemate/Roommate Role. In
CFA, results indicated this 3-factor model fit acceptably well and replicated in the second
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split half sample (RMSEA = 0.052 (90% CI: 0.047, 0.057); CFI = 0.933; TLI = 0.923).
However, model fit was substantially poorer in the configural invariance model (RMSEA
= 0.042 (90% CI: 0.041, 0.044); CFI = 0.822; TLI = 0.811). Because CFI and TLI fit
indices decreased below a priori cutoffs for adequate model fit, configural invariance fit
was determined to be too inadequate to warrant further invariance testing. Accordingly,
the 3-factor model of the items of the PFI administered in MATCH was non-invariant
over baseline and post-treatment timepoints. These poor findings may be due to the fact
that MATCH administered an abbreviated version of the PFI.
Despite these findings, the PFI performed reasonably well on internal consistency
and convergent validity analyses. Except for the Housemate/Roommate role factor (α =
0.531), internal consistency was good: total PFI α = 0.867, Subjective Role Performance
factor α = 0.817, Overall Social Role Performance factor α = 0.818 (see Table 8). Further,
the convergent validity results were all significant (p < 0.001) and in the expected
direction. The PFI was significantly, negatively correlated with SSTI (r = -0.200) and
BDI (r = -0.380).
The PFI performed poorly with respect to sensitivity/specificity and adequately
detected only some consumption outcomes, as detailed in Table 17. Total PFI summary
scores only adequately detected 4 of 15 post-treatment outcomes (AUC’s = 0.538-0.700)
and failed to adequately detect any consumption outcomes at 12-month follow-up
(AUC’s = 0.533-0.600). Since CFA results indicated an adequately-fitting 3-factor
structure, these 3 factor summary scores were examined via ROC curve analyses,
yielding very few positive results. The Subjective Role Performance factor failed to
adequately detect any post-treatment (AUC’s = 0.522-0.644) or 12-month follow-up
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outcomes (AUC’s = 0.517-0.582). The Overall Social Role Performance factor
adequately detected only 1 of 15 post-treatment consumption outcomes (AUC’s = 0.5200.663) and the Housemate/Roommate Role factor only adequately detected 2 of 15 posttreatment outcomes (AUC’s = 0.537-0.660). Neither the Overall Social Role Performance
factor nor the Housemate/Roommate Role factor adequately detected any 12-month
follow-up outcomes (AUC’s = 0.517-0.582, 0.531-0.585). There was no consistent
pattern for which post-treatment or 12-month follow-up outcomes yielded highest AUC’s
when detected by the PFI total summary score or any of the factors, but 2+ level change
in WHO risk level since baseline (calculated via DPD) and 12-month abstinence were the
lowest AUC’s for all 4 PFI variables. As reported in Appendix A, only 2 items
adequately detected any consumption outcomes: Item 11 (spousal/mate overall role
performance; Social Role Performance factor) and 19 (housemate/roommate overall role
performance).
Alcohol-Abstinence Self-Efficacy Scale. The Alcohol-Abstinence Self-Efficacy
Scale (AASE; DiClemente et al., 1994) was tested in both COMBINE and MATCH for
the present study. Since the bulk of previous studies have found a 4-factor model in
previous administrations of the AASE, this model was tested via CFA. This model
provided an adequate fit in COMBINE (replication half fit indices: RMSEA = 0.050
(90% CI: 0.048, 0.053); CFI = 0.919; TLI = 0.914), but failed to provide an adequate fit
in the overall MATCH dataset (split half 1 sub-sample fit indices: RMSEA = 0.060 (90%
CI: 0.058, 0.062); CFI = 0.866; TLI = 0.857). An additional CFA was conducted to
examine the fit of this 4-factor model in each treatment arm (aftercare and outpatient) for
three reasons: 1) known differences in participant characteristics in the treatment arms of
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Project MATCH, 2) the fact that the previously published 4-factor model of the AASE fit
acceptably well in COMBINE, and 3) that the present study aimed for measurement
preservation rather than data-driven methodology that could limit generalizability of
findings. As shown in Table 7, the model fit adequately in the outpatient treatment arm of
MATCH (replication half fit indices: RMSEA = 0.050 (90% CI: 0.047, 0.053); CFI =
0.931; TLI = 0.926). Moreover, this 4-factor model was invariant across time through
strong invariance in both COMBINE and MATCH: COMBINE strong invariance
RMSEA = 0.033 (90% CI: 0.032, 0.034); CFI = 0.953; TLI = 0.954; MATCH outpatient
arm strong invariance RMSEA = 0.027 (90% CI: 0.026, 0.029); CFI = 0.917; TLI =
0.914.
Despite the strong invariance across baseline and post-treatment timepoints that
replicated in both COMBINE and MATCH, however, other properties of the AASE were
less promising. As described in Table 8, internal consistency of the overall AASE was
good (α = 0.752 in COMBINE; α = 0.841 in MATCH) but internal consistency of each of
the 4 factors was sub-optimal in both COMBINE and MATCH (COMBINE, MATCH:
Negative Affect factor α = 0.356, 0.557; Social/Positive factor α = 0.341, 0.460; Physical
& Other Concern factor α = 0.162, 0.546; and Withdrawal & Urges factor α = 0.279,
0.458). However, internal consistency is greatly influenced by the number of items
contained in a measure or factor, so these low internal consistency reliability values may
be because the AASE is a brief questionnaire.
More importantly, there were mixed findings for the convergent validity of the
AASE. In COMBINE and MATCH, the AASE and its 4 factors were only significantly
correlated with some of the Form 90 consumption variables and since the AASE purports
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to measure craving and temptation to drink, one would expect all Form 90 consumption
variables to be significantly correlated with the AASE. In COMBINE and MATCH, the
total AASE correlations were: PDA r = -0.012 (p > 0.05) and r = -0.063 (p < 0.01);
PHDD r = 0.011 (p > 0.05) and r = 0.062 (p < 0.05); DDD r = 0.079 (p < 0.01) and r =
0.032 (p > 0.05); MXD r = 0.104 (p < 0.001) and r = 0.061 (p < 0.05); and DPD r =
0.070 (p > 0.05) and r = 0.067 (p < 0.01). Bivariate correlations were similarly mixed for
each of the 4 factors in COMBINE and MATCH.
Sensitivity/specificity of the AASE and the 4 subscales were all below the AUC >
0.650 cutoff for all post-treatment and 12-month follow-up outcomes in both COMBINE
and MATCH (detailed in Tables 18 and 19). This suggests the total AASE summary
score and 4 factors are markedly poor at detecting concurrent and future consumption
outcomes.
One potential exception to the poor sensitivity/specificity of the AASE in
COMBINE and MATCH was the notably strong AUC values for the Temptation and
Confidence subscales of the AASE. The summary scores of items in each of these 2
categories of items (Confidence and Temptation) were examined in terms of their
sensitivity/specificity (presented in Tables 18 and 19). In the COMBINE Study, the
summary of Confidence items and summary of Temptation items each adequately
detected all concurrent (AUC’s = 0.674-0.879, 0.669-0.858) and 12-month follow-up
consumption outcomes (AUC’s = 0.664-0.732, 0.690-0.734). In Project MATCH, the
summary of Confidence items adequately detected 13 of 15 post-treatment (AUC’s =
0.611-0.733) and 10 of 11 12-month follow-up consumption outcomes (AUC’s = 0.6490.690). Similarly, the summary of Temptation items in MATCH adequately detected 11
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of 15 post-treatment (AUC’s = 0.537-0.655) and all 11 12-month follow-up consumption
outcomes (AUC’s = 0.655-0.712). No consistent pattern emerged for which posttreatment or 12-month consumption outcomes yielded highest AUC’s for the AASE
Confidence or Temptation subscales across COMBINE and MATCH, except that 12month composite clinical outcome of moderate or lower risk had the highest AUC’s for
both Confidence and Temptation subscales in both COMBINE and MATCH.
Consideration was given to these two summary scores via preliminary CFA
testing of the AASE as a 2-factor solution; however, model fit was inadequate and not
explored further (COMBINE split half 1 fit indices: RMSEA = 0.068 (90% CI: 0.065,
0.070); CFI = 0.897; TLI = 0.889; MATCH full sample split half 1 fit indices: RMSEA =
0.053 (90% CI: 0.050, 0.055); CFI = 0.856; TLI = 0.848). Future research should
investigate these two summary scores further given their strong sensitivity/specificity for
detecting consumption outcomes.
The Addiction Severity Index. Because the original ASI was not administered in
Project MATCH, numerous strategies were employed to identify a factor model to test
via CFA (detailed in Table 7). First, a 3-factor model based on the structure described by
McLellan and colleagues (1992) was tested and failed to converge. Then, that model was
altered to account for the restricted distributions of data in MATCH and the high
intercorrelations between items; this model also failed to converge. Next, item question
content and data distributions were explored closely to identify overlapping question
content and to identify response categories that could be collapsed to mitigate potential
data sparseness. No alternative factor structures emerged successfully from these
procedures.
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The total ASI score, as administered in Project MATCH, also performed poorly
from other psychometric perspectives. The total ASI internal consistency was poor (α =
0.327), which is unsurprising given the content of the items differed substantially from
one category (e.g., legal problems) to the next (e.g., psychological problems). Convergent
validity results yielded mixed findings whereby the total ASI score was significantly
correlated with some but not all Form 90 consumption variables. Specifically, the ASI
was significantly correlated with DPD and MXD (r = 0.068, p < 0.01; r = 0.064, p <
0.01), but these low correlation values may have been significant due to the large sample
size of Project MATCH. All other convergent validity results were non-significant,
including other consumption variables (e.g., PDA, PHDD), temptation items, PFI, ESI,
and Alcoholic Anonymous Involvement (p’s < 0.05). Finally, the ASI failed to detect any
post-treatment or 12-month follow-up consumption outcomes over the AUC > 0.650
level. Post-treatment consumption outcomes were detected at AUC values between 0.494
and 0.612; 12-month follow-up consumption outcomes were detected at AUC values
between 0.492 and 0.544 (detailed in Table 20). Accordingly, the ASI as administered in
Project MATCH had poor construct validity, internal consistency, convergent validity,
and sensitivity/specificity to detect consumption outcomes.
ROC Curve Analyses of Consumption Variables
Results indicated that both PDA and PHDD were largely adequately
sensitive/specific to detect consumption-based outcomes per the AUC > 0.65 a priori
cutoff (presented in Table 21). In the COMBINE Study, post-treatment outcome AUC
values for PDA and PHDD ranged from 0.670 to 0.988. AUC values for both PDA and
PHDD were largest for detecting specific WHO risk levels and composite clinical scores
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and lowest for detecting changes in WHO risk level since baseline timepoint. These
overall patterns were replicated in the post-treatment MATCH data (month 3) where
AUC values ranged from 0.610 to 0.994 with specific WHO risk levels and composite
clinical scores had highest AUC’s and changes in WHO risk had lowest AUC’s.
For ROC curve analyses of post-treatment PDA and PHDD detecting 12-month
follow-up consumption outcomes, all AUC values were lower than for those of congruent
timepoints in COMBINE and MATCH (described above). AUC values for PDA and
PHDD detecting 12-month follow-up consumption outcomes ranged from 0.682 to 0.798
in COMBINE data and 0.668 to 0.754 in MATCH. Given the small range in AUC values,
no clear pattern emerged as to which 12-month follow-up outcomes were most or least
easily detected via PDA or PHDD in COMBINE or MATCH.
Discussion
The current study was a secondary analysis of data from the two largest
randomized clinical trials for alcohol use disorder (AUD) ever conducted (the COMBINE
Study (Anton et al., 2006) and Project MATCH (Project MATCH Research Group,
1996)) to examine the measurement stability, internal consistency reliability, construct
and convergent validity, sensitivity, and specificity of numerous non-consumption
outcome measures. These analyses constitute some of the most broad and rigorous
analyses ever conducted with these measures of non-consumption constructs. Such
extensive analyses of measures administered in the COMBINE Study and Project
MATCH have highlighted several promising measures for use in future research.
Although no one construct performed consistency well across all measures tested,
individual measures stood out as viable options for measuring a variety of constructs. The
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Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), and the brief World
Health Organization Quality of Life measure (WHOQOL-BREF) as administered in
COMBINE or MATCH demonstrated strong viability for future use as measures of
psychological health and quality of life. Importantly, these three measures had good
construct validity and were invariant across time, which supports their use for examining
pre- to post-treatment changes in these constructs. Moreover, these three measures
adequately detected at least some consumption outcomes, as illustrated via ROC curve
analyses. These administrations of the BSI, BDI, and WHOQOL-BREF in COMBINE
and MATCH also had good convergent validity and internal consistency reliability.
Other measures administered in COMBINE and MATCH yielded mixed findings.
Measures that showed the most promise for use in AUD treatment research were the
Obsessive-Compulsive Drinking Scale (OCDS) and the Drinker Inventory of
Consequences (DrInC) due to their having evidence for at least partial measurement
invariance across time and at least some evidence for their sensitivity/specificity to detect
consumption outcomes. Since the main goal of the present study was to identify measures
that may be viable for use in examining pre- and post-treatment changes for AUD
treatment research, more credence was given to these results (i.e., invariance,
sensitivity/specificity) as more directly related to the research question. As such, the
OCDS and DrInC were shown to have the most promise and minor refinement may
further improve their suitability for use in AUD treatment research.
Findings from the present study also highlighted a few measures that warrant
further investigation and refinement for use in AUD treatment research. The Spielberger
State-Trait Inventory (SSTI) had strong internal consistency and construct validity, but
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more research is needed to improve the convergent validity and sensitivity/specificity.
The Short Form Health Survey (SF-12) and the Psychosocial Functioning Inventory (PFI)
each had acceptable convergent validity, strong internal consistency, strong convergent
validity, and had acceptable sensitivity/specificity but more research is needed to
establish more robust factor structures that will be invariant across time. The Alcohol
Abstinence Self-Efficacy Scale (AASE) had acceptable construct validity and was
invariant across time in both COMBINE and MATCH, had acceptable internal
consistency, and had acceptable convergent validity. However, the AASE had poor
sensitivity/specificity in both COMBINE and MATCH for detecting all post-treatment
and 12-month follow-up consumption outcomes. However, ROC curve results from the
present study highlighted the good sensitivity/specificity of the AASE Confidence and
Temptation subscales and future research may be able to use these two subscales rather
than the total AASE score to examine pre- and post-treatment differences in self-efficacy
and temptation to drink.
Only the Addiction Severity Index (ASI), as administered in MATCH, failed to
perform adequately across all psychometric analyses. Data distributions appeared to be
driving the poor performance of the ASI, which likely indicates that aggregating data
from the ASI items is counter to its utility. The content of individual items in the ASI
may still be useful in clinical settings and in research from an individual participant
perspective. For instance, it may be interesting and informative clinically and in research
to know the number of times an individual client or participant has experienced each of
the psychiatric symptoms or engaged in specific illegal activities that are each assessed
via the ASI. However, summarizing items and averaging scores across clients based on
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the published ASI factor structure does not appear to be advisable based on the present
findings. These findings are consistent with previously published cautions against the
ASI (DeJong et al., 1995).
The limitations highlighted by the ASI and the mixed results for many other
measures administered in the COMBINE Study and Project MATCH highlight an
important gap in current AUD treatment research: a need for more rigorously developed
assessment tools. Although the COMBINE Study and Project MATCH utilized the state
of the science assessment tools, many of the measures that were used in these studies
continue to be used in current research despite a lack of clear psychometric strength. The
present results highlight that many non-consumption measures are viable or promising
for use in future research; however, non-consumption measures could be even stronger
psychometrically. First, more stringent, empirically-driven methodologies should be used
to develop measures whereas many currently used measures were developed solely by
researchers. Ideally, measurement development is a multiphase process where a measure
is developed iteratively based on data from multiple sources, including experts,
researchers, and study populations themselves (e.g., the Delphi process; Polit & Hungler,
1999). Second, more extensive and appropriate psychometric analyses should be
conducted for measures before they become widely used. Many of the previously
published studies of measures’ psychometric appropriateness of use in AUD treatment
research stemmed from internal consistency and principal components analyses (PCA).
However, many psychometricians would argue that internal consistency is not the sole,
nor best, metric for evaluating reliability. Further, PCA is ill-suited for examining factor
structure and construct validity (e.g., Floyd & Widaman, 1995). Instead, other forms of
55

reliability and validity testing could be used in initial measurement development (e.g.,
test-retest reliability, confirmatory factor analyses; DeVellis, 2012). Unsurprisingly, the
measures that performed the best in the present study (the Brief Symptom Inventory,
Beck Depression Inventory, and the World Health Organization Quality of Life, Brief
version) were three of the more rigorously developed and evaluated measures utilized in
the COMBINE Study and Project MATCH. With more rigorously developed measures, it
is entirely possible that non-consumption variables would yield consistently strong results
and AUD researchers would no longer need to use consumption variables as “surrogates”
for these more clinically meaningful, non-consumption constructs.
With respect to consumption outcomes being necessary as “surrogates” for nonconsumption outcomes, it is important to note that the present study found evidence to
contradict this assumption. Many non-consumption variables were not exceptionally bad
at detecting consumption outcomes and numerous non-consumption measures had large
effect sizes, even when aggregated across the overall samples in the COMBINE Study
and Project MATCH. For example, the Drinker Inventory of Consequences (DrInC) and
the 3 factors identified in the present study, the Obsessive-Compulsive Drinking Scale
(OCDS) and the 4 factors used in the present study, and the Confidence and Temptation
subscales of the Alcohol-Abstinence Self-Efficacy (AASE) all had good
sensitivity/specificity for detecting consumption outcomes and demonstrated large effect
sizes, especially in the COMBINE Study. These findings are despite the long-standing
claim that consumption variables must be used as a “surrogate” for more clinically
meaningful non-consumption outcomes due to the inability of non-consumption
outcomes to be sensitive to change (e.g., FDA, 2015, p. 2). Although area under the curve
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(AUC) values were generally higher for consumption variables detecting consumption
outcomes than those for non-consumption variables, several non-consumption variables
performed adequately and several non-consumption variables had AUC values
comparable to those for consumption variables. For example, the 3-factor model of the
DrInC described in the present study yielded AUC values similar to those of consumption
variables, especially in the COMBINE Study. Some AUC values for the DrInC subscales
in COMBINE were as high as 0.939, which corresponds to an almost perfect
detection/discrimination ability. The DrInC corresponds to alcohol-related consequences
that are far more aligned with diagnostic criteria for AUD than consumption variables,
which have never been part of diagnostic criteria used by the American Psychiatric
Association.
Another interesting finding was a general pattern of which consumption outcomes
were adequately detected or not detected by non-consumption variables. The majority of
non-consumption variables had their highest AUC values for composite clinical outcome
scores (especially the heavy drinking/problems or lower risk level) for both posttreatment and 12-month follow-up timelines. The post-treatment outcome that yielded the
lowest AUC’s by the majority of non-consumption variables was the 2+ levels of change
in WHO risk level from baseline. The 12-month consumption outcome that yielded the
lowest AUC’s by many non-consumption variables was 12-month abstinence. These
patterns were largely consistent with consumption variable ROC curve results (PDA and
PHDD ROC curve analyses), suggesting that post-treatment WHO Risk Level changes
from baseline and 12-month abstinence may not be the best outcomes to use in evaluating
treatment efficacy given the difficulty of accurately detecting these outcomes. Instead,
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the present findings suggest future research evaluate treatment efficacy based on the most
readily detected outcome: composite clinical score. The composite clinical scores that
systematically yielded the highest AUC’s for both consumption and non-consumption
variables were moderate or lower risk and heavy drinking/problems or lower risk.
Recent studies have suggested the shift in WHO risk level, as a consumption
based outcome, may provide a viable alternative to abstinence and percent subjects with
no heavy drinking days as endpoints for alcohol clinical trials (Hasin et al., in press;
Witkiewitz et al., 2017). In the current study, the method of calculation of the WHO risk
level variables impacted how those consumption outcomes were detected by both nonconsumption variables as well as PDA and PHDD. Specifically, WHO risk levels
calculated via drinks per drinking day (DDD), maximum number of drinks consumed in
the 90-day window (MXD) and drinks per day in the assessment window (averaged
across drinking and abstinent days; DPD) yielded inconsistent AUC values across
variables. For some variables, AUC values were relatively equitable across DDD, MXD,
and DPD calculations. However, for some variables such as the Beck Depression
Inventory scores and Drinker Inventory of Consequences (in Project MATCH
especially), AUC values varied substantively between DDD, MXD, and DPD
calculations of WHO risk levels. These findings suggest more research is needed to
establish which calculation method (DDD, MXD, or DPD) is most stable across various
conditions. Further, the fact that sensitivity/specificity can vary so meaningfully in
consumption outcomes is another indication that consumption variables may not be as
dependable as previously assumed by AUD treatment researchers.
Limitations
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The primary limitation of the present study was that findings are specific to
administration of the measures in the COMBINE Study and Project MATCH. Many of
the measures examined in the present study were abbreviated versions of the full
measures. For example, the WHOQOL-BREF as administered in COMBINE was one
item short of the full WHOQOL-BREF. It is unclear why one item was omitted in the
COMBINE Study, though it seems likely the item was omitted erroneously since it is the
last item of the measure. However, the WHOQOL-BREF as administered in COMBINE
performed well despite this missing item. Other abbreviated measures did not perform so
well. Notably, the ASI, SSTI, and PFI were all abbreviated versions of these measures,
which may or may not account for the poor results found for these measures in MATCH
compared to previous studies (e.g., Feragne, 1983; McLellan et al., 1980). The results
from the present study provide evidence that abbreviated versions of measures should be
thoroughly explored psychometrically prior to their use in AUD treatment research.
The present findings are also limited by the availability of certain measures at
different assessment periods. The post-treatment WHOQOL-BREF in COMBINE was
administered at week 26, which fails to map on to the week 16 data that were examined
for other measures. This inconsistency restricted the examination of post-treatment ROC
curves for WHOQOL-BREF. Moreover, baseline data were only available for the SSTI,
which prevented the examination of measurement invariance of the 4-factor model that fit
excellently in MATCH data.
Another limitation of the present study was that the administration of identical
measures may have varied between COMBINE and MATCH. For instance, the ROC
curve analyses of the DrInC differed between COMBINE and MATCH, which may be
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the result of how this measure was administered. The DrInC was inconsistently
administered to individuals who reported total abstinence during the assessment window
in Project MATCH and was administered to all individuals in the COMBINE Study,
regardless of drinking status. These differences in assessment administration could
explain why ROC curve results were inconsistent between the two studies. Further, the
bivariate correlations had mixed results than were predicted for MATCH (but not
COMBINE), which may indicate the DrInC as administered in MATCH was unstable
psychometrically. Future administrations of the DrInC in other longitudinal studies may
help elucidate these nuances to identify if the DrInC is poorly suited for longitudinal
research or if methodology employed in MATCH was ill-suited for the DrInC.
Similarly, two of the three measures that performed most strongly in the present
analyses (the BSI and WHOQOL-BREF) were only administered in the COMBINE
Study. COMBINE was a smaller and more homogeneous sample than Project MATCH
(primarily due to more strict alcohol consumption and diagnostic inclusion criteria in
COMBINE). It is unclear how these two measures may perform in more heterogeneous
samples. The current findings may not be generalizable to other studies and replication of
the present findings is warranted.
Finally, findings from the present study may be limited by the fact that the full
samples in COMBINE and MATCH were used. Analyses from Project MATCH included
both aftercare and outpatient arms, which had different demographic characteristics and
different levels of AUD severity (the aftercare arm had greater baseline drinking and
severity than the outpatient arm). These differences may be one factor that could have
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hurt the psychometrics of examined measures. Findings from the present study should be
examined in other studies to attempt replication.
Future Directions
Findings from the present study highlight strengths in several non-consumption
measures for use in AUD treatment research. However, the present study also
demonstrates that not all measures are created equally. For instance, although both the
WHOQOL-BREF and the SF-12 are purported to measure quality of life, the SF-12 was
non-invariant across time. Examining the items reveals that many items are “doublebarreled,” meaning they essentially ask more than one question per item (e.g., “…how
much of the time has your physical health or emotional problems interfered with your
social activities…”), which is particularly problematic when a measure was
conceptualized as measuring two separate factors: physical and psychological health.
These “double-barreled” items may be problematic for invariance of a measure across
time because participants may respond predominantly to one aspect of the question item
(e.g., physical health interference in social activities) at one timepoint and to another
aspect of the question (e.g., emotional problem interference in social activities) at another
timepoint. Careful development of question items comprising measures to avoid “doublebarreled” items and other pitfalls of measurement development and refinement are
essential in future research (see recommendations by DeVellis, 2012; Miller et al., 2009).
As the measures currently exist, it is recommended that future research use the
WHOQOL-BREF rather than the SF-12 to assess changes in quality of life over time.
In addition to highlighting the need for future research to refine existing and
develop new measures of non-consumption constructs, future research should prioritize
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consistent administration of assessment tools. Assessments should be administered at
multiple timepoints whenever possible, so future research can expand the extant
knowledge of measurement invariance of commonly used assessment tools. The
measurement non-invariance of several measures examined in the present study
highlights the need for future research on testing for measurement invariance across time
as well as across other domains such as gender, race, treatment sample, and other
demographic characteristics.
Most importantly, the present study highlights the promise of several nonconsumption measures as viable means of examining clinically meaningful outcomes in
AUD treatment research beyond changes in alcohol consumption alone. Accordingly,
future researchers are supported in expanding their definitions of treatment success to
include at least psychological health (via the BSI and BDI) and quality of life (via the
WHOQOL-BREF). Additional research is needed to continue this vein of research to
discover and develop other potentially viable measures that map onto definitions of
treatment success used by clinicians as well as clients and their loved ones (Kaskutas et
al., 2014; Neale et al., 2014). Future research need not rely solely upon consumptionbased outcome variables due to a lack of information on which measures are appropriate
to use in AUD treatment research. Several non-consumption measures showed promise
and more measures could be refined and developed to allow researchers to further
enhance their ability to examine treatment efficacy using non-consumption outcomes.
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Figure 1
Summary of methods used in the present study

Note. (C) = COMBINE Study; (M) = Project MATCH. Abbreviated measure names are: Drinker
Inventory of Consequences (DrInC), Short Inventory of Problems (SIP), Addiction Severity
Index (ASI), Alcohol Abstinence Self-Efficacy Scale (AASE), Obsessive-Compulsive Drinking
Scale (OCDS), Brief Symptom Inventory (BSI), Beck Depression Inventory (BDI), Spielberger
State-Trait Inventory (SSTI), World Health Organization Quality of Life brief version
(WHOQOL-BREF), Health Survey (SF-12), Psychosocial Functioning Inventory (PFI).
Abbreviated terms are: WHO = World Health Organization; DDD = drinks per drinking day;
MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days), CCO = Composite
Clinical Outcome, mod = moderate.
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Table 1
Demographic, design, and exclusion criteria for COMBINE and MATCH
COMBINE
Demographic characteristic
Sample size
1383
Gender -- % Male
69.1%
Age – Mean (SD)
44.4 (10.2)
Ethnicity -- % White
76.8%
Marital status -- % Married, in relationship
46.3%
Employment status -- % Full or part-time
71.4%
Higher education or equivalent
70.6%
Design
Randomization to treatment
9 groups
Length of treatment
16 weeks
Follow-up assessments
12 months
Exclusion criteria
Age
18+
Meet criteria for abuse/dependence
Past year
Reading level
Literate
Comorbid psychiatric diagnoses
X
Unable to identify collateral informant
Severe cognitive impairment
Residential instability
Other illicit drug dependence
X
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MATCH
1726
75.7%
40.2 (10.9)
80.0%
41.4%
82.1%
53.4%
3 groups
12 weeks
12 months
18+
Past year
6th grade
X
X
X
X
X

Table 2
Outcome variables and their corresponding measures and timepoints available in COMBINE and MATCH
Variable
Measure in COMBINE (C) or
Timepoint(s) assessed in COMBINE (C) or MATCH (M)
MATCH (M)
Alcohol/
Form-90 (C, M)
Pre-treatment (C, M), During-treatment (C, M), PostDrug use
treatment (C, M)
Drinking
Consequences
/Severity

Mental health

Craving/
Temptation

Drinker Inventory of Consequences/
Short Inventory of Problems
(DrInC/SIP; C, M)

Pre-treatment (C, M), During-treatment (C, M), Posttreatment (C, M)

Addiction Severity Index (ASI; M)

Pre-treatment (M), During-treatment (M), Post-treatment
(M)

Brief Symptom Inventory (BSI; C)

Pre-treatment (C), During-treatment (C), Post-treatment
(C)

Beck Depression Inventory (BDI;
M)

Pre-treatment (M), During-treatment (M), Post-treatment
(M)

Spielberger State-Trait Inventory
(SSTI; M)

Pre-treatment (M), During-treatment (M), Post-treatment
(M)

Alcohol Abstinence Self-Efficacy
(AASE; C, M)

Pre-treatment (C, M), During-treatment (C, M), Posttreatment (C, M)

Obsessive-Compulsive Drinking
Scale (OCDS; C)

Pre-treatment (C), During-treatment (C), Post-treatment
(C)

Temptation/craving items during
treatment (M)

Pre-treatment (M), During-treatment (M), Post-treatment
(M)
65

Quality of
life/
Functioning

World Health Organization Quality
of Life (WHOQOL-BREF; C)

Pre-treatment (C), During-treatment (C), Post-treatment
(C)

Health Survey (SF-12; C)

Pre-treatment (C), During-treatment (C), Post-treatment
(C)

Psychosocial Functioning Inventory
(PFI; M)

Pre-treatment (M), During-treatment (M), Post-treatment
(M)
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Table 3
Outcome variables and the measures hypothesized to have convergent (+, significant positive correlation; -, significant
negative correlation) validity in COMBINE and MATCH

Form90

DrInC,
ASI

BSI,
SSTI,
BDI

OCDS,
Temptation/
craving
items

PFI,
WHOQOLBREF

SF-12

ESI

AASE

AAI

Form-90
+
+
DrInC, ASI
+
+
BSI, SSTI,
BDI
OCDS,
Temptation/
+
+
craving
PFI,
WHOQOLBREF
SF-12
ESI
AASE
AAI
Note. Abbreviated measure names are: Drinker Inventory of Consequences (DrInC), Addiction Severity Index (ASI), Brief Symptom
Inventory (BSI), Spielberger State-Trait Inventory (SSTI), Beck Depression Inventory (BDI), Obsessive-Compulsive Drinking Scale
(OCDS), Psychosocial Functioning Inventory (PFI), World Health Organization Quality of Life brief version (WHOQOL-BREF),
Health Survey (SF-12), Employment Status and Income (ESI), Alcohol Abstinence Self-Efficacy Scale (AASE), and Alcoholics
Anonymous Involvement (AAI).
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Table 4
Descriptive statistics and Cohen’s d effect sizes for measures used in the present study at
baseline, post-treatment (post-tx), and 12-month follow-up (12mo)
N
M (SD)
Cohen’s d
Percent Days
Baseline:
1383 21.41 (22.50) Baseline to PostAbstinent:
tx: 1.809
COMBINE Study
Post-Tx:
1288 72.66 (33.49) Post-tx to 12mo:
0.277
12mo:
1099 62.63 (39.12) Baseline to 12mo:
1.331
Percent Days
Baseline:
1725 30.90 (29.96) Baseline to PostAbstinent: Project
tx: 1.786
MATCH
Post-Tx:
1657 83.17 (28.51) Post-tx to 12moth: 0.208
12mo:
1594 76.69 (33.55) Baseline to 12mo:
1.443
Percent Heavy
Baseline:
1383 70.52 (26.57) Baseline to PostDrinking Days:
tx: 1.919
COMBINE Study
Post-Tx:
1288 17.54 (28.69) Post-tx to 12mo:
0.275
12mo:
1171 26.20 (34.27) Baseline to 12mo:
1.461
Percent Heavy
Baseline:
1725 63.18 (31.43) Baseline to PostDrinking Days:
tx: 1.780
Project MATCH
Post-Tx:
1657 12.46 (25.09) Post-tx to 12mo:
0.156
12mo:
1594 16.71 (29.17) Baseline to 12mo:
1.530
DrInC: COMBINE
Baseline:
1381 47.61 (20.42) Baseline to PostStudy
tx: 1.735
Post-Tx:
1098 13.36 (18.85) Post-tx to 12mo:
0.322
12mo:
965
19.89 (21.81) Baseline to 12mo:
1.320
Physical Health Baseline:
1381 9.28 (4.36)
Baseline to PostSubscale
tx: 1.607
Post-Tx:
1098 2.61 (3.87)
Post-tx to 12mo:
0.320
12mo:
965
3.95 (4.53)
Baseline to 12mo:
1.203
Interpersonal
Baseline:
1381 10.06 (6.01) Baseline to PostSubscale
tx: 1.389
Post-Tx:
1098 2.60 (4.44)
Post-tx to 12mo:
0.302
12mo:
965
4.06 (5.25)
Baseline to 12mo:
1.051
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Intrapersonal
Subscale

Impulse
Subscale

Social
Responsibility
Subscale

DrInC: Project
MATCH

Physical Health
Subscale

Interpersonal
Subscale

Intrapersonal
Subscale

Impulse
Subscale

Baseline:

1381

Post-Tx:

1098

12mo:

965

Baseline:

1381

Post-Tx:

1098

12mo:

965

Baseline:

1381

Post-Tx:

1098

12mo:

965

Baseline:

1703

Post-Tx:

985

12mo:

789

Baseline:

1626

Post-Tx:

966

12mo:

818

Baseline:

1558

Post-Tx:

942

12mo:

807

Baseline:

1626

Post-Tx:

964

12mo:

819

Baseline:

1572
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14.44 (5.66)

Baseline to Posttx: 1.749
4.45 (5.78)
Post-tx to 12mo:
0.292
6.26 (6.66)
Baseline to 12mo:
1.343
7.56 (4.25)
Baseline to Posttx: 1.414
2.11 (3.29)
Post-tx to 12mo:
0.318
3.24 (3.83)
Baseline to 12mo:
1.058
6.27 (4.15)
Baseline to Posttx: 1.260
1.60 (3.04)
Post-tx to 12mo:
0.242
2.39 (3.46)
Baseline to 12mo:
1.000
52.63 (23.32) Baseline to Posttx: 0.680
35.86 (26.78) Post-tx to 12mo:
0.323
27.50 (24.70) Baseline to 12mo:
1.057
9.48 (4.94)
Baseline to Posttx: 0.666
6.14 (5.13)
Post-tx to
12moFU: 0.204
5.12 (4.85)
Baseline to 12mo:
0.945
12.21 (6.98) Baseline to Posttx: 0.568
8.17 (7.34)
Post-tx to 12mo:
0.295
6.09 (6.72)
Baseline to 12mo:
0.888
14.51 (6.02) Baseline to Posttx: 0.653
10.38 (6.81) Post-tx to 12mo:
0.297
8.31 (7.16)
Baseline to 12mo:
0.965
8.69 (5.10)
Baseline to Posttx: 0.503

Social
Responsibility
Subscale

ASI Psychiatric
Severity: Project
MATCH

ASI Family
History: Project
MATCH
ASI Legal Status:
Project MATCH
OCDS: COMBINE
Study

AASE: COMBINE
Study

Confidence
Subscale
Temptation
Subscale
AASE: Project
MATCH

Confidence
Subscale
Temptation
Subscale

Post-Tx:

967

6.06 (5.43)

12mo:

820

3.41 (4.21)

Baseline:

1598

7.49 (4.71)

Post-Tx:

964

4.71 (4.69)

12mo:

822

4.73 (4.56)

Baseline:

1714

0.21 (0.20)

Post-Tx:

1566

0.14 (0.19)

12mo:

1554

0.13 (0.19)

Baseline:

1726

2.65 (48.04)

Baseline:

1726

Baseline:

1383

141.90
(384.71)
26.60 (8.20)

Post-Tx:
12mo:
Baseline:

1101
2
1382

Post-Tx:

1103

Baseline:

1377

11.25 (9.32)
22.50 (6.36)
113.26
(15.39)
114.78
(14.71)
2.61 (0.74)

Post-Tx:
Baseline:

1100
1374

3.50 (0.92)
3.11 (0.78)

Post-Tx:
Baseline:

1093
1700

Post-Tx:

1557

Baseline:

1662

2.28 (0.85)
117.37
(21.48)
114.56
(21.87)
3.06 (0.92)

Post-Tx:
Baseline:

1528
1688

3.51 (1.00)
2.91 (0.90)
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Post-tx to 12mo:
0.540
Baseline to 12mo:
1.097
Baseline to Posttx: 0.591
Post-tx to 12mo:
0.004
Baseline to 12mo:
0.592
Baseline to Posttx: 0.358
Post-tx to 12mo:
0.053
Baseline to 12mo:
0.410
-

Baseline to Posttx: 1.762
Baseline to Posttx: 0.101
Baseline to Posttx: 1.078
Baseline to Posttx: 1.022
Baseline to Posttx: 0.130
Baseline to Posttx: 0.469
Baseline to Posttx: 0.674

Temptation Item:
Project MATCH
AAI: Project
MATCH
BSI: COMBINE
Study

Somatic
Subscale

Obsessive
Compulsive
Subscale

Interpersonal
Sensitivity
Subscale

Depression
Subscale

Anxiety
Subscale

Hostility
Subscale

Post-Tx:
Baseline:

1545
1531

2.31 (0.88)
2.66 (1.34)

-

Baseline:

1624

4.29 (2.60)

-

Baseline:

1356

Post-Tx:

1101

12mo:

959

Baseline:

1356

Post-Tx:

1101

12mo:

959

Baseline:

1356

Post-Tx:

1101

12mo:

959

Baseline:

1356

Post-Tx:

1101

12mo:

959

Baseline:

1356

Post-Tx:

1101

12mo:

959

Baseline:

1356

Post-Tx:

1101

12mo:

959

Baseline:

1356

Post-Tx:

1101

60.29 (10.91) Baseline to Posttx: 0.695
52.32 (12.11) Post-tx to 12mo:
0.031
51.93 (13.18) Baseline to 12mo:
0.702
54.50 (10.37) Baseline to Posttx: 0.467
49.89 (9.24) Post-tx to 12mo:
0.123
51.10 (10.14) Baseline to 12mo:
0.331
58.69 (10.75) Baseline to Posttx: 0.560
52.66 (10.78) Post-tx to 12mo:
0.014
52.81 (11.38) Baseline to 12mo:
0.534
56.75 (10.96) Baseline to Posttx: 0.405
52.44 (10.24) Post-tx to 12mo:
0.061
51.81 (10.45) Baseline to 12mo:
0.459
61.55 (10.60) Baseline to Posttx: 0.603
55.15 (10.64) Post-tx to 12mo:
0.001
55.16 (11.15) Baseline to 12mo:
0.590
58.37 (11.48) Baseline to Posttx: 0.628
51.26 (11.11) Post-tx to 12mo:
0.012
51.12 (11.44) Baseline to 12mo:
0.632
55.68 (9.65) Baseline to Posttx: 0.584
50.04 (9.67) Post-tx to 12mo:
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Phobic Anxiety
Subscale

Paranoia
Subscale

Psychoticism
Subscale

BDI: Project
MATCH

SSTI: Project
MATCH (full
SSTI)
SSTI: Project
MATCH (items
used in factor
analyses)
WHOQOL-BREF:
COMBINE Study

Physical Health
Subscale

12mo:

959

49.32 (9.93)

Baseline:

1356

53.43 (9.45)

Post-Tx:

1101

51.10 (8.13)

12mo:
Baseline:

959
1356

50.89 (8.40)
54.53 (10.45)

Post-Tx:

1101

51.47 (9.61)

12mo:

959

50.46 (9.97)

Baseline:

1356

63.29 (10.09)

Post-Tx:

1101

56.73 (10.69)

12mo:

959

56.67 (11.00)

Baseline:

1618

10.17 (8.24)

Post-Tx:

1532

7.57 (7.87)

12mo:

1505

7.94 (8.40)

Baseline:

1553

27.70 (7.14)

0.103
Baseline to 12mo:
0.651
Baseline to Posttx: 0.262
Post-tx to 12mo:
0.025
0.281
Baseline to Posttx: 0.304
Post-tx to 12mo:
0.103
Baseline to 12mo:
0.397
Baseline to Posttx: 0.633
Post-tx to 12mo:
0.006
Baseline to 12mo:
0.632
Baseline to Posttx: 0.322
Post-tx to 12mo:
0.045
Baseline to 12mo:
0.268
-

Baseline:

1553

25.79 (6.67)

-

Baseline:

1351

Post-Tx:

1062

12mo:

954

Baseline:

1351

Post-Tx:

1060

12mo:

954

87.94 (13.44) Baseline to Posttx: 0.679
97.67 (15.38) Post-tx to 12mo:
0.257
93.88 (14.06) Baseline to 12mo:
0.434
27.29 (4.30) Baseline to Posttx: 0.420
29.11 (4.38) Post-tx to 12mo:
0.037
28.95 (4.36) Baseline to 12mo:
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0.384
Psychological
Baseline:
1351 21.04 (3.97) Baseline to PostHealth Subscale
tx: 0.417
Post-Tx:
1060 22.75 (4.27) Post-tx to 12mo:
0.022
12mo:
954
22.84 (4.03) Baseline to 12mo:
0.451
Social Subscale Baseline:
1351 9.84 (2.63)
Baseline to Posttx: 0.373
Post-Tx:
1060 10.82 (2.62) Post-tx to 12mo:
0.008
12mo:
953
10.84 (2.52) Baseline to 12mo:
0.389
Environment
Baseline:
1351 29.77 (5.44) Baseline to PostSubscale
tx: 0.280
Post-Tx:
1060 31.31 (5.57) Post-tx to 12mo:
0.007
12mo:
954
31.27 (5.49) Baseline to 12mo:
0.275
SF-12: COMBINE
Baseline:
1357 42.28 (7.14) Baseline to PostStudy
tx: 0.710
Post-Tx:
1102 47.13 (6.43) Post-tx to 12mo:
0.275
12mo:
951
45.26 (7.18) Baseline to 12mo:
0.416
Physical Health Baseline:
1346 0.27 (0.83)
Baseline to PostSubscale
tx: 0.129
Post-Tx:
1099 0.37 (0.70)
Post-tx to 12mo:
0.244
12mo:
948
0.18 (0.86)
Baseline to 12mo:
0.107
Psychological
Baseline:
1346 -0.86 (1.10)
Baseline to PostHealth Subscale
tx: 0.760
Post-Tx:
1099 -0.07 (0.96)
Post-tx to 12mo:
0.130
12mo:
948
-0.20 (1.04)
Baseline to 12mo:
0.614
PFI: Project
Baseline:
1695 50.91 (11.42) Baseline to PostMATCH
tx: 0.532
Post-Tx:
1556 56.88 (10.98) Note. Abbreviated measure names are: Drinker Inventory of Consequences (DrInC), Addiction
Severity Index (ASI), Brief Symptom Inventory (BSI), Spielberger State-Trait Inventory (SSTI),
Beck Depression Inventory (BDI), Obsessive-Compulsive Drinking Scale (OCDS), Psychosocial
Functioning Inventory (PFI), World Health Organization Quality of Life brief version
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(WHOQOL-BREF), Health Survey (SF-12), Employment Status and Income (ESI), Alcohol
Abstinence Self-Efficacy Scale (AASE), and Alcoholics Anonymous Involvement (AAI).
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Table 5
Frequencies for dichotomous consumption outcome variables used in Receiver Operating
Characteristic (ROC) Curve analyses at post-treatment (post-tx) and 12-month follow-up (12mo)
COMBINE Study
Project MATCH
0 = 829
0 = 807
Post-tx Abstinence
1 = 459
1 = 850
N = 1288
N = 1657
0 = 858
0 = 1017
Post-tx Heavy Drinking
1 = 630
1 = 640
N = 1288
N = 1657
0 = 699
0 = 692
Post-tx WHO risk: low risk or
1 = 589
1 = 965
lower risk computed via DDD
N = 1288
N = 1657
0 = 751
0 = 720
Post-tx WHO risk: low risk or
1 = 537
1 = 937
lower risk computed via MXD
N = 1288
N = 1657
0 = 325
0 = 304
Post-tx WHO risk: low risk or
1 = 963
1 = 1353
lower risk computed via DPD
N = 1288
N = 1657
Post-tx WHO risk: moderate
0 = 544
0 = 592
risk or lower risk computed
1 = 744
1 = 1065
via DDD
N = 1288
N = 1657
Post-tx WHO risk: moderate
0 = 641
0 = 645
risk or lower risk computed
1 = 647
1 = 1012
via MXD
N = 1288
N = 1657
Post-tx WHO risk: moderate
0 = 199
0 = 219
risk or lower risk computed
1 = 1089
1 = 1438
via DPD
N = 1288
N = 1657
0 = 666
0 = 1057
Post-tx Composite clinical
1 = 471
1 = 599
Outcome: Abstinent
N = 1137
N = 1656
Post-tx Composite clinical
0 = 348
0 = 850
Outcome: Moderate drinking
1 = 789
1 = 806
or abstinent
N = 1137
N = 1656
Post-tx Composite clinical
0 = 98
0 = 531
Outcome: Heavy drinking OR
1 = 1039
1 = 1125
problems, moderate drinking,
N = 1137
N = 1656
or abstinent
1 or more risk level change in
0 = 473
0 = 571
WHO risk level baseline to
1 = 763
1 = 1069
post-tx (computed via DDD)
N = 1236
N = 1640
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1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
12mo Abstinence

12mo Heavy Drinking
12mo WHO risk: low risk or
lower risk computed via DDD
12mo WHO risk: low risk or
lower risk computed via MXD
12mo WHO risk: low risk or
lower risk computed via DPD
12mo WHO risk: moderate
risk or lower risk computed
via DDD
12mo WHO risk: moderate
risk or lower risk computed
via MXD
12mo WHO risk: moderate
risk or lower risk computed
via DPD
12mo Composite clinical
Outcome: Abstinent
12mo Composite clinical
Outcome: Moderate drinking
or abstinent

0 = 261
1 = 975
N = 1236
0 = 686
1 = 550
N = 1236
0 = 493
1 = 743
N = 1236
0 = 817
1 = 355
N = 1172
0 = 539
1 = 633
N = 1172
0 = 719
1 = 453
N = 1172
0 = 756
1 = 416
N = 1172
0 = 448
1 = 724
N = 1172

0 = 335
1 = 1305
N = 1640
0 = 784
1 = 856
N = 1640
0 = 624
1 = 1016
N = 1640
0 = 847
1 = 747
N = 1594
0 = 923
1 = 671
N = 1594
0 = 729
1 = 865
N = 1594
0 = 763
1 = 831
N = 1594
0 = 384
1 = 1210
N = 1594

0 = 581
1 = 591
N = 1172
0 = 646
1 = 526
N = 1172
0 = 323
1 = 849
N = 1172
0 = 750
1 = 284
N = 1034
0 = 554
1 = 480
N = 1034

0 = 615
1 = 979
N = 1594
0 = 682
1 = 912
N = 1594
0 = 255
1 = 1339
N = 1594
0 = 1024
1 = 581
N = 1605
0 = 827
1 = 778
N = 1605
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12mo Composite clinical
Outcome: Heavy drinking OR
problems, moderate drinking,
or abstinent

0 = 234
1 = 800
N = 1034
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0 = 488
1 = 1117
N = 1605

Table 6
Summary of Psychometric Findings across Measures and Methods (0 = Poor Psychometric Qualities; 1 = Mixed or Modest
Psychometric Qualities; and 2 = Acceptable to Excellent Psychometric Qualities)
Measure (Study: COMBINE (C) or MATCH (M))
ROC
Reliability
Convergent CFA
Invariance Total
Validity
Points/
Possible
Points
Alcohol Abstinence Self-Efficacy Scale (AASE) (C;
0
1
1
1
2
5/10
M)
AASE-Confidence (C; M)
2
N/A
N/A
N/A
N/A
2/2
AASE-Temptation (C; M)
2
N/A
N/A
N/A
N/A
2/2
Addiction Severity Index (M)
0
0
0
0
0
0/10
Beck Depression Inventory (M)
1
2
2
2
2
9/10
Brief Symptom Inventory (C)
1
2
2
2
2
9/10
Drinker Inventory of Consequences (C; M)
1
2
1
1
2
7/10
Obsessive-Compulsive Drinking Scale (C)
2
2
2
1
1
8/10
Psychosocial Functioning Inventory (M)
1
2
2
1
0
6/10
Short Form Health Survey-12 (C)
1
2
2
1
0
6/10
Spielberger State-Trait Inventory (M)
0
2
1
2
N/A
5/8
WHO Quality of Life Scale - Brief (C)
N/A
2
2
1
2
7/8
Note. ROC. Sensitivity/specificity scores of 0 indicated area under the curve (AUC) < 0.650 across all outcomes; 1 point indicated
AUC > 0.650 and < 0.700 or mixed results across studies or across consumption outcomes; 2 points indicated AUC > 0.700 in both
COMBINE and MATCH or for most outcomes. Internal consistency reliability scores of 0 indicated α < 0.70; 1 point indicated α >
0.70 and < 0.80 or mixed results across studies; 2 points indicated α > 0.80 in both COMBINE and MATCH. Convergent validity
results with scores of 0 indicated non-significant (p > 0.05) or at least one correlation in the opposite direction than was expected; 1
point indicated significant correlations with some but not all the expected measures or mixed results across studies; 2 points indicated
significant correlations in the expected direction for all measures in both COMBINE and MATCH. Confirmatory factor analysis
(CFA) results with scores of 0 indicated RMSEA > 0.08 or CFI or TLI < 0.90; 1 point indicated RMSEA < 0.08 and > 0.06 and/or CFI
or TLI > 0.90 and < 0.95 or mixed results across studies; 2 points indicated RMSEA < 0.06 and CFI or TLI > 0.95 in both COMBINE
and MATCH. Measurement invariance results with scores of 0 indicated non-invariance at the configural level or did not proceed to
invariance testing due to poor model fit; 1 point indicated at least adequate model fit through the metric invariance testing (constraint
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of the factor loadings for equivalence) or mixed results across both studies; 2 points indicated good model fit through strong
invariance testing (highest possible level of invariance for categorical data) in both COMBINE and MATCH.
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Table 7
Model results for CFA and measurement invariance testing
Measure (Dataset)
CFA Model
Invariance Testing Model
AASE
4-factors based on
(COMBINE)
DiClemente et al., 1994
structure
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
AASE (MATCH)
4-factors based on
DiClemente et al., 1994
structure*
AASE (MATCH
4-factors based on
aftercare arm only) DiClemente et al., 1994
structure
AASE (MATCH
4-factors based on
outpatient arm
DiClemente et al., 1994
only)
structure
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
ASI (MATCH)
3-Factor Solution based on
McLellan et al., 1992
structure*
Modified 3-Factor Solution
based on McLellan et al.,
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RMSEA (90% CI)
0.050 (0.048,
0.053)

CFI
0.919

TLI
0.914

0.030 (0.029,
0.031)
0.029 (0.028,
0.030)
0.033 (0.032,
0.034)
0.060 (0.058,
0.062)

0.964

0.963

0.964

0.964

0.953

0.954

0.866

0.857

0.081 (0.078,
0.084)

0.879

0.872

0.050 (0.047,
0.053)

0.931

0.926

0.027 (0.026,
0.029)
0.027 (0.026,
0.029)
0.028 (0.026,
0.029)
N/A (failed
convergence)

0.917

0.914

0.915

0.913

0.912

0.912

N/A

N/A

N/A (failed
convergence)

N/A

N/A

BDI (MATCH)

1992 structure with items
ASIAF1, ASIAF2, ASIAF3,
ASIAF6, ASIAF7, ASIAF8
specified as categorical per
limited distributions and
with item ASIAL13
removed due to high
correlations with other
variables and sparseness in
item endorsement.
2-factors (cognitiveaffective and somatic
factors)
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
3-factors (negative attitude,
performance impairment,
and somatic factors)
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment

BSI (COMBINE)

9-factors based on
Derogatis & Melisaratos,
1983 structure
Configural: Baseline to
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0.030 (0.025,
0.035)

0.978

0.975

0.019 (0.017,
0.021)
0.018 (0.016,
0.020)
0.019 (0.017,
0.021)
0.027 (0.021,
0.032)

0.971

0.970

0.973

0.972

0.968

0.969

0.982

0.980

0.019 (0.017,
0.020)
0.018 (0.016,
0.020)
0.019 (0.017,
0.021)
0.022 (0.019,
0.025)

0.973

0.971

0.975

0.974

0.970

0.971

0.975

0.974

0.011 (0.010,

0.981

0.980

Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
DrInC (COMBINE) 5-factors based on original
conceptualization*
1-factor based on previously
published models*
3-factor solution based on
my conceptualization of the
DrInC as comprised of
consequences that occur
commonly, moderately, and
rarely
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
DrInC (MATCH)

3-factor solution based on
my conceptualization of the
DrInC as comprised of
consequences that occur
commonly, moderately, and
rarely
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
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0.012)
0.011 (0.009,
0.012)
0.012 (0.011,
0.013)
0.044 (0.041,
0.046)
0.051 (0.049,
0.054)
0.041 (0.038,
0.043)

0.982

0.981

0.977

0.977

0.900

0.894

0.861

0.854

0.920

0.916

0.017 (0.016,
0.019)
0.019 (0.018,
0.020)
0.024 (0.023,
0.025)
0.040 (0.038,
0.042)

0.975

0.974

0.969

0.968

0.951

0.952

0.908

0.904

0.018 (0.017,
0.019)
0.018 (0.017,
0.018)
0.018 (0.017,

0.945

0.944

0.946

0.946

0.941

0.942

Baseline to Post-Treatment
SIP (COMBINE) 5-factors based on original
conceptualization
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
1-factor based on previously
published models*
SIP (MATCH) 5-factors based on original
conceptualization
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment

0.019)
0.061 (0.053,
0.069)
0.086 (0.084,
0.086)
N/A (Not tested due
to failed configural
invariance)
N/A (Not tested due
to failed configural
invariance)
0.109 (0.102,
0.116)
0.077 (0.070,
0.084)
0.059 (0.057,
0.061)
N/A (Not tested due
to failed configural
invariance)
N/A (Not tested due
to failed configural
invariance)

0.969

0.960

0.894

0.883

N/A

N/A

N/A

N/A

0.890

0.871

0.949

0.933

0.894

0.883

N/A

N/A

N/A

N/A

0.109 (0.102,
0.117)

0.852

0.823

0.123 (0.114,
0.131)

0.869

0.837

OCDS
(COMBINE)
2-factor model based on
Ansseau et al., 2000; Anton
2000; Cordero et al., 2009*
2-factor model based on
Ansseau et al., 2000; Anton
2000; Cordero et al., 2009
with consumption items
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removed*
3-factor model based on
Roberts et al., 1999*
3-factor model based on
Kranzler et al., 1999*
4-factor model based on
Bohn et al., 1996*
4-factor model based on
Connor et al., 2008*
4-factor model based on
previous published
structures, EFA results, and
conceptualization of items
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
PFI (MATCH)

3-factor model based on
original conceptualization
of factors available in
MATCH abbreviated
version of the PFI
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment
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0.096 (0.089,
0.104)
0.104 (0.096,
0.111)
0.100 (0.093,
0.108)
0.084 (0.076,
0.091)
0.072 (0.062,
0.082)

0.889

0.863

0.881

0.841

0.885

0.852

0.920

0.897

0.968

0.956

0.032 (0.029,
0.036)
0.035 (0.032,
0.038)
0.076 (0.073,
0.079)
0.052 (0.047,
0.057)

0.987

0.984

0.984

0.981

0.910

0.912

0.933

0.923

0.042 (0.041,
0.822
0.044)
N/A (Not tested due N/A
to failed configural
invariance)
N/A (Not tested due N/A
to failed configural
invariance)

0.811
N/A

N/A

SF-12 (COMBINE)

2-factor model based on
previously published
models
Configural: Baseline to
Post-Treatment
Loadings Constrained:
Baseline to Post-Treatment
Thresholds Constrained:
Baseline to Post-Treatment

SSTI (MATCH)
only administered
at baseline

WHOQOL-BREF
(COMBINE)

2-factor model based on
previously published
models*
4-factor model based on
original conceptualization
of 7 factors (items for 4 of
the 7 factors were available
in MATCH)
4-factor, higher order model
based on Skevington et al.,
2004 structure
Model 1: Baseline to Week
26 (N=1381)
Model 2: Baseline to Week
26
Model 3: Baseline to Week
26
Model 4: Baseline to Week
26
Model 5: Baseline to Week
26
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0.080 (0.071,
0.090)

0.951

0.939

0.075 (0.072,
0.078)
N/A (Not tested due
to failed configural
invariance)
N/A (Not tested due
to failed configural
invariance)
0.116 (0.109,
0.122)

0.854

0.839

N/A

N/A

N/A

N/A

0.902

0.884

0.056 (0.048,
0.064)

0.976

0.969

0.050 (0.045,
0.055)

0.942

0.935

0.037 (0.035-0.038)

0.921

0.916

0.035 (0.034-0.037)

0.926

0.923

0.035 (0.033-0.037)

0.927

0.924

0.033 (0.032-0.035)

0.927

0.931

0.035 (0.033-0.036)

0.920

0.925

Model 1: Week 26 to Week
52
Model 2: Week 26 to Week
52
Model 3: Week 26 to Week
52
Model 4: Week 26 to Week
52
Model 5: Week 26 to Week
52
4-factor model based on
Jaracz et al., 2006 structure
4-factor model based on
Trompenaars et al., 2005
structure
4-factor model based on
Yao & Wu, 2002 structure

0.042 (0.040-0.044)

0.917

0.912

0.040 (0.038-0.041)

0.924

0.921

0.039 (0.038-0.041)

0.925

0.922

0.039 (0.036-0.039)

0.925

0.929

0.037 (0.036-0.039)

0.926

0.930

0.053 (0.048-0.058)

0.944

0.936

0.053 (0.048-0.058)

0.938

0.930

Non-positive
definite matrix

N/A

N/A

Note. CFA results are for the replication split half sample unless specified as the first split half via *
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Table 8
Baseline measure internal consistency reliability
Measure
Subscale (from CFA)
AASE (COMBINE)
Negative Affect
Social/Positive
Physical & Other Concern
Withdrawal & Urges
AASE (MATCH)
Negative Affect
Social/Positive
Physical & Other Concern
Withdrawal & Urges
ASI
BDI
2-Factor Model: Cognitive-Affective
2-Factor Model: Somatic
3-Factor Model: Negative Attitudes
3-Factor Model: Performance Impairment
3-Factor Model: Somatic
BSI
Somatization
Obsessive-Compulsive
Depression
Interpersonal Sensitivity
Hostility
Anxiety
Psychoticism
Phobic Anxiety
Paranoid Ideation
DrInC (COMBINE)
Common Consequences
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Cronbach’s Alpha
0.752*
0.356
0.341
0.162
0.279
0.841**
0.557
0.460
0.546
0.458
0.327
0.889**
0.848**
0.771*
0.859**
0.739*
0.478
0.965**
0.798*
0.862**
0.882**
0.643
0.790*
0.824**
0.864**
0.786*
0.836**
0.937**
0.855**

Moderately Common Consequences
Rare Consequences
DrInC (MATCH)
Common Consequences
Moderately Common Consequences
Rare Consequences
OCDS
PFI
Subjective Role Performance
Overall Social Role Performance
Housemate/Roommate Role
SF-12
Physical Health
Psychological Health
SSTI
“Factor 1” by Forgays et al., 1997
“Factor 2” by Forgays et al., 1997
“Factor 4” by Forgays et al., 1997
“Factor 6” by Forgays et al., 1997
WHOQOL-BREF
Physical Health
Psychological Health
Social Relationships
Environment

0.905**
0.808**
0.938**
0.833**
0.905**
0.830**
0.852**
0.867**
0.817**
0.818**
0.531
0.874**
0.805**
0.861**
0.887**
0.746*
0.865**
0.496
0.781*
0.901**
0.798*
0.770*
0.718*
0.812**

Note. * indicates good internal consistency of α > 0.70 and < 0.80; ** indicates excellent internal consistency of α > 0.80.
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Table 9
Receiver operating characteristic curve area under the curve (AUC) results for the Brief Symptom Inventory (BSI) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
BSI
SOM
OC
DEP
IS
HOS
ANX
PSY PHOB PARA
total
Factor Factor Factor Factor Factor Factor Factor Factor Factor
score
Post-tx Abstinence
0.628
0.613
0.617
0.626 0.622 0.602 0.606 0.600 0.566 0.575
Post-tx Heavy Drinking
0.676
0.629
0.644
0.672 0.667 0.636 0.652 0.648 0.610 0.619
Post-tx WHO risk: low risk or
0.658
0.622
0.634
0.661 0.650 0.619 0.645 0.634 0.594 0.603
lower risk computed via DDD
Post-tx WHO risk: low risk or
0.650
0.617
0.627
0.652 0.642 0.624 0.631 0.620 0.589 0.598
lower risk computed via MXD
Post-tx WHO risk: low risk or
0.690
0.674
0.691
0.695 0.672 0.627 0.693 0.650 0.608 0.609
lower risk computed via DPD
Post-tx WHO risk: moderate
risk or lower risk computed via 0.675
0.641
0.650
0.670 0.662 0.627 0.656 0.647 0.613 0.619
DDD
Post-tx WHO risk: moderate
risk or lower risk computed via 0.670
0.634
0.645
0.667 0.662 0.633 0.650 0.641 0.606 0.614
MXD
Post-tx WHO risk: moderate
risk or lower risk computed via 0.724
0.683
0.714
0.718 0.695 0.666 0.731 0.655 0.624 0.623
DPD
Post-tx Composite clinical
0.638
0.624
0.619
0.639 0.636 0.612 0.622 0.610 0.575 0.583
Outcome: Abstinent
Post-tx Composite clinical
Outcome: Moderate drinking or 0.746
0.698
0.710
0.744 0.723 0.677 0.735 0.704 0.639 0.646
abstinent
Post-tx Composite clinical
Outcome: Heavy drinking OR
0.833
0.767
0.796
0.833 0.809 0.754 0.799 0.774 0.713 0.721
problems, moderate drinking,
or abstinent
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1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
12mo Abstinence
12mo Heavy Drinking
12mo WHO risk: low risk or
lower risk computed via DDD
12mo WHO risk: low risk or
lower risk computed via MXD
12mo WHO risk: low risk or
lower risk computed via DPD
12mo WHO risk: moderate risk
or lower risk computed via
DDD
12mo WHO risk: moderate risk
or lower risk computed via
MXD
12mo WHO risk: moderate risk
or lower risk computed via
DPD
12mo Composite clinical
Outcome: Abstinent
12mo Composite clinical

0.603

0.569

0.587

0.606

0.595

0.567

0.605

0.585

0.569

0.573

0.591

0.529

0.568

0.601

0.564

0.581

0.589

0.565

0.535

0.539

0.511

0.581

0.588

0.616

0.592

0.581

0.599

0.593

0.568

0.574

0.585

0.550

0.574

0.584

0.570

0.567

0.580

0.566

0.550

0.554

0.545
0.603

0.549
0.569

0.543
0.578

0.555
0.608

0.543
0.580

0.557
0.600

0.541
0.585

0.539
0.601

0.508
0.557

0.512
0.562

0.599

0.581

0.580

0.610

0.582

0.593

0.592

0.596

0.556

0.560

0.589

0.573

0.576

0.596

0.579

0.588

0.577

0.583

0.546

0.550

0.602

0.568

0.604

0.619

0.578

0.589

0.600

0.597

0.551

0.551

0.618

0.580

0.587

0.627

0.597

0.599

0.605

0.523

0.574

0.578

0.603

0.578

0.579

0.611

0.583

0.597

0.588

0.599

0.562

0.566

0.613

0.572

0.594

0.627

0.590

0.586

0.607

0.610

0.562

0.568

0.550

0.556

0.545

0.562

0.547

0.557

0.543

0.552

0.522

0.523

0.625

0.586

0.604

0.639
90

0.612

0.619

0.606

0.620

0.571

0.574

Outcome: Moderate drinking or
abstinent
12mo Composite clinical
Outcome: Heavy drinking OR
0.708
0.638
0.686
0.706 0.648 0.691 0.677 0.686 0.647 0.650
problems, moderate drinking,
or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). BSI sub-scale factors are: Somatic symptoms (SOM),
Obsessive-Compulsive symptoms (OC), Depressive symptoms (DEP), Interpersonal Sensitivity (IS), Hostility (HOS), Anxiety
symptoms (ANX), Psychoticism symptoms (PSY), Phobic Anxiety symptoms (PHOB), and Paranoia symptoms (PARA). AUC >
0.650 have been bolded and underlined for improved readability.
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Table 10
Receiver operating characteristic curve area under the curve (AUC) results for the Beck Depression Inventory (BDI) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
3-Factor
2-Factor
2-Factor
3-Factor
3-Factor
Solution:
BDI total
Solution:
Solution:
Solution:
Solution:
Performance
score
Cognitive
Somatic
Negative
Somatic
Impairment
Factor
Factor
Affect Factor
Factor
Factor
Post-tx Abstinence
0.582
0.606
0.598
0.626
0.585
0.558
Post-tx Heavy Drinking
0.597
0.636
0.616
0.654
0.604
0.571
Post-tx WHO risk: low risk or
0.598
0.633
0.619
0.653
0.605
0.575
lower risk computed via DDD
Post-tx WHO risk: low risk or
0.589
0.625
0.612
0.645
0.602
0.569
lower risk computed via MXD
Post-tx WHO risk: low risk or
0.653
0.689
0.706
0.701
0.680
0.658
lower risk computed via DPD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.600
0.641
0.624
0.659
0.611
0.577
DDD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.595
0.634
0.615
0.651
0.603
0.569
MXD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.658
0.705
0.710
0.714
0.685
0.668
DPD
Post-tx Composite clinical
0.588
0.604
0.594
0.625
0.580
0.554
Outcome: Abstinent
Post-tx Composite clinical
Outcome: Moderate drinking
0.613
0.640
0.639
0.665
0.615
0.585
or abstinent
Post-tx Composite clinical
0.624
0.656
0.655
0.678
0.633
0.596
Outcome: Heavy drinking OR
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problems, moderate drinking,
or abstinent
1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
12mo Abstinence
12mo Heavy Drinking
12mo WHO risk: low risk or
lower risk computed via DDD
12mo WHO risk: low risk or
lower risk computed via MXD
12mo WHO risk: low risk or
lower risk computed via DPD
12mo WHO risk: moderate
risk or lower risk computed via
DDD
12mo WHO risk: moderate
risk or lower risk computed via
MXD
12mo WHO risk: moderate
risk or lower risk computed via
DPD
12mo Composite clinical

0.630

0.608

0.593

0.626

0.579

0.563

0.586

0.584

0.570

0.592

0.573

0.537

0.604

0.587

0.570

0.606

0.562

0.541

0.555

0.538

0.530

0.551

0.531

0.508

0.596
0.623

0.558
0.574

0.556
0.579

0.574
0.591

0.553
0.571

0.523
0.539

0.619

0.577

0.576

0.593

0.570

0.537

0.610

0.564

0.574

0.580

0.566

0.530

0.674

0.597

0.607

0.615

0.592

0.572

0.631

0.586

0.587

0.604

0.583

0.536

0.624

0.574

0.582

0.593

0.573

0.539

0.669

0.586

0.606

0.603

0.599

0.569

0.623

0.565

0.566
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0.582

0.564

0.533

Outcome: Abstinent
12mo Composite clinical
Outcome: Moderate drinking
0.667
0.595
0.604
0.617
0.593
0.558
or abstinent
12mo Composite clinical
Outcome: Heavy drinking OR
0.681
0.621
0.630
0.635
0.622
0.572
problems, moderate drinking,
or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 11
Receiver operating characteristic curve area under the curve (AUC) results for the World Health Organization Quality of Life Brief
scale (WHOQOL-BREF) for detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
WHOQOL-BREF
Psychological
Environment
Physical Factor
Social Factor
total score
Factor
Factor
12mo Abstinence
0.508
0.555
0.569
0.583
0.556
12mo Heavy Drinking
0.643
0.620
0.630
0.627
0.609
12mo WHO risk: low risk or
0.631
0.604
0.615
0.620
0.603
lower risk computed via DDD
12mo WHO risk: low risk or
0.623
0.595
0.604
0.616
0.595
lower risk computed via MXD
12mo WHO risk: low risk or
0.632
0.616
0.635
0.612
0.579
lower risk computed via DPD
12mo WHO risk: moderate risk
or lower risk computed via
0.664
0.638
0.652
0.642
0.629
DDD
12mo WHO risk: moderate risk
or lower risk computed via
0.644
0.618
0.630
0.632
0.610
MXD
12mo WHO risk: moderate risk
or lower risk computed via
0.651
0.633
0.659
0.627
0.591
DPD
12mo Composite clinical
0.610
0.589
0.609
0.597
0.581
Outcome: Abstinent
12mo Composite clinical
Outcome: Moderate drinking or
0.668
0.644
0.665
0.638
0.624
abstinent
12mo Composite clinical
Outcome: Heavy drinking OR
0.715
0.698
0.704
0.691
0.653
problems, moderate drinking, or
abstinent
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Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 12
Receiver operating characteristic curve area under the curve (AUC) results for the Obsessive-Compulsive Drinking Scale (OCDS) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
OCDS total
Factor 1
Factor 2
Factor 3
Factor 4
score
Post-tx Abstinence
0.864
0.659
0.657
0.773
0.832
Post-tx Heavy Drinking
0.846
0.671
0.697
0.775
0.826
Post-tx WHO risk: low risk or lower risk computed via
0.846
0.668
0.683
0.766
0.825
DDD
Post-tx WHO risk: low risk or lower risk computed via
0.863
0.668
0.674
0.780
0.838
MXD
Post-tx WHO risk: low risk or lower risk computed via
0.868
0.669
0.708
0.751
0.851
DPD
Post-tx WHO risk: moderate risk or lower risk
0.819
0.667
0.710
0.763
0.806
computed via DDD
Post-tx WHO risk: moderate risk or lower risk
0.844
0.667
0.689
0.768
0.823
computed via MXD
Post-tx WHO risk: moderate risk or lower risk
0.876
0.684
0.758
0.763
0.851
computed via DPD
Post-tx Composite clinical Outcome: Abstinent
0.857
0.673
0.666
0.766
0.820
Post-tx Composite clinical Outcome: Moderate drinking
0.919
0.726
0.771
0.821
0.888
or abstinent
Post-tx Composite clinical Outcome: Heavy drinking
0.934
0.782
0.871
0.877
0.912
OR problems, moderate drinking, or abstinent
1 or more risk level change in WHO risk level baseline
0.686
0.610
0.629
0.646
0.676
to post-tx (computed via DDD)
1 or more risk level change in WHO risk level baseline
0.709
0.618
0.614
0.658
0.701
to post-tx (computed via DPD)
2 or more risk level change in WHO risk level baseline
0.732
0.620
0.627
0.675
0.719
to post-tx (computed via DDD)
2 or more risk level change in WHO risk level baseline
0.696
0.589
0.627
0.631
0.686
to post-tx (computed via DPD)
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12mo Abstinence
0.709
0.604
0.566
0.643
0.695
12mo Heavy Drinking
0.695
0.606
0.603
0.644
0.684
12mo WHO risk: low risk or lower risk computed via
0.717
0.626
0.599
0.661
0.703
DDD
12mo WHO risk: low risk or lower risk computed via
0.730
0.627
0.599
0.667
0.716
MXD
12mo WHO risk: low risk or lower risk computed via
0.729
0.616
0.602
0.659
0.718
DPD
12mo WHO risk: moderate risk or lower risk computed
0.690
0.616
0.620
0.647
0.682
via DDD
12mo WHO risk: moderate risk or lower risk computed
0.693
0.603
0.599
0.641
0.684
via MXD
12mo WHO risk: moderate risk or lower risk computed
0.728
0.630
0.623
0.666
0.718
via DPD
12mo Composite clinical Outcome: Abstinent
0.734
0.614
0.587
0.681
0.721
12mo Composite clinical Outcome: Moderate drinking
0.756
0.647
0.629
0.694
0.742
or abstinent
12mo Composite clinical Outcome: Heavy drinking OR
0.737
0.668
0.672
0.716
0.722
problems, moderate drinking, or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 13
Receiver operating characteristic curve area under the curve (AUC) results for the Drinker Inventory of Consequences (DrInC) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in the COMBINE Study
Factor 2
Factor 1
COMBINE DrInC
(Moderately
Factor 3 (Rare
(Common
total score
Common
Consequences)
Consequences)
Consequences)
Post-tx Abstinence
0.845
0.833
0.803
0.780
Post-tx Heavy Drinking
0.845
0.840
0.824
0.782
Post-tx WHO risk: low risk or lower risk computed via
0.841
0.835
0.810
0.775
DDD
Post-tx WHO risk: low risk or lower risk computed via
0.843
0.834
0.807
0.774
MXD
Post-tx WHO risk: low risk or lower risk computed via
0.825
0.825
0.716
0.771
DPD
Post-tx WHO risk: moderate risk or lower risk
0.831
0.821
0.814
0.781
computed via DDD
Post-tx WHO risk: moderate risk or lower risk
0.841
0.835
0.819
0.780
computed via MXD
Post-tx WHO risk: moderate risk or lower risk
0.859
0.842
0.853
0.821
computed via DPD
Post-tx Composite clinical Outcome: Abstinent
0.846
0.834
0.801
0.784
Post-tx Composite clinical Outcome: Moderate
0.921
0.909
0.914
0.870
drinking or abstinent
Post-tx Composite clinical Outcome: Heavy drinking
0.944
0.939
0.939
0.917
OR problems, moderate drinking, or abstinent
1 or more risk level change in WHO risk level baseline
0.701
0.692
0.687
0.673
to post-tx (computed via DDD)
1 or more risk level change in WHO risk level baseline
0.691
0.687
0.677
0.655
to post-tx (computed via DPD)
2 or more risk level change in WHO risk level baseline
0.731
0.722
0.713
0.688
to post-tx (computed via DDD)
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2 or more risk level change in WHO risk level baseline
0.677
0.677
0.663
0.642
to post-tx (computed via DPD)
12mo Abstinence
0.684
0.671
0.659
0.645
12mo Heavy Drinking
0.702
0.685
0.683
0.674
12mo WHO risk: low risk or lower risk computed via
0.705
0.696
0.681
0.663
DDD
12mo WHO risk: low risk or lower risk computed via
0.712
0.702
0.685
0.669
MXD
12mo WHO risk: low risk or lower risk computed via
0.710
0.711
0.688
0.662
DPD
12mo WHO risk: moderate risk or lower risk computed
0.699
0.688
0.683
0.668
via DDD
12mo WHO risk: moderate risk or lower risk computed
0.700
0.686
0.681
0.670
via MXD
12mo WHO risk: moderate risk or lower risk computed
0.712
0.709
0.692
0.677
via DPD
12mo Composite clinical Outcome: Abstinent
0.705
0.694
0.689
0.663
12mo Composite clinical Outcome: Moderate drinking
0.736
0.719
0.715
0.699
or abstinent
12mo Composite clinical Outcome: Heavy drinking OR
0.755
0.748
0.747
0.727
problems, moderate drinking, or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 14
Receiver operating characteristic curve area under the curve (AUC) results for the Drinker Inventory of Consequences (DrInC) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in Project MATCH
Factor 2
Factor 1
MATCH DrInC total
(Moderately
Factor 3 (Rare
(Common
score
Common
Consequences)
Consequences)
Consequences)
Post-tx Abstinence
0.583
0.585
0.573
0.586
Post-tx Heavy Drinking
0.679
0.672
0.673
0.671
Post-tx WHO risk: low risk or lower risk computed via
0.658
0.650
0.651
0.654
DDD
Post-tx WHO risk: low risk or lower risk computed via
0.642
0.637
0.635
0.639
MXD
Post-tx WHO risk: low risk or lower risk computed via
0.675
0.747
0.756
0.718
DPD
Post-tx WHO risk: moderate risk or lower risk
0.688
0.678
0.683
0.680
computed via DDD
Post-tx WHO risk: moderate risk or lower risk
0.677
0.669
0.671
0.671
computed via MXD
Post-tx WHO risk: moderate risk or lower risk
0.784
0.778
0.787
0.737
computed via DPD
Post-tx Composite clinical Outcome: Abstinent
0.652
0.649
0.647
0.631
Post-tx Composite clinical Outcome: Moderate
0.886
0.850
0.879
0.876
drinking or abstinent
Post-tx Composite clinical Outcome: Heavy drinking
0.836
0.812
0.835
0.809
OR problems, moderate drinking, or abstinent
1 or more risk level change in WHO risk level baseline
0.579
0.590
0.589
0.597
to post-tx (computed via DDD)
1 or more risk level change in WHO risk level baseline
0.549
0.541
0.550
0.568
to post-tx (computed via DPD)
2 or more risk level change in WHO risk level baseline
0.550
0.558
0.554
0.569
to post-tx (computed via DDD)
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2 or more risk level change in WHO risk level baseline
0.493
0.508
0.495
0.513
to post-tx (computed via DPD)
12mo Abstinence
0.424
0.432
0.425
0.436
12mo Heavy Drinking
0.511
0.515
0.511
0.509
12mo WHO risk: low risk or lower risk computed via
0.499
0.505
0.496
0.504
DDD
12mo WHO risk: low risk or lower risk computed via
0.470
0.473
0.468
0.478
MXD
12mo WHO risk: low risk or lower risk computed via
0.557
0.569
0.561
0.535
DPD
12mo WHO risk: moderate risk or lower risk computed
0.547
0.553
0.543
0.546
via DDD
12mo WHO risk: moderate risk or lower risk computed
0.507
0.517
0.506
0.508
via MXD
12mo WHO risk: moderate risk or lower risk computed
0.575
0.581
0.582
0.547
via DPD
12mo Composite clinical Outcome: Abstinent
0.453
0.465
0.455
0.462
12mo Composite clinical Outcome: Moderate drinking
0.558
0.566
0.558
0.549
or abstinent
12mo Composite clinical Outcome: Heavy drinking OR
0.590
0.598
0.589
0.573
problems, moderate drinking, or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 15
Receiver operating characteristic curve area under the curve (AUC) results for the baseline Spielberger State-Trait Inventory (SSTI)
for detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
SSTI total
score
“Factor 1”
“Factor 2”
“Factor 4”
“Factor 6”
SSTI total
(CFA
by Forgays
by Forgays
by Forgays by Forgays
score
items
et al., 1997
et al., 1997
et al., 1997 et al., 1997
only)
Post-tx Abstinence
0.524
0.526
0.514
0.529
0.524
0.500
Post-tx Heavy Drinking
0.549
0.548
0.538
0.544
0.546
0.518
Post-tx WHO risk: low risk or
0.540
0.540
0.536
0.539
0.539
0.508
lower risk computed via DDD
Post-tx WHO risk: low risk or
0.530
0.530
0.523
0.533
0.530
0.502
lower risk computed via MXD
Post-tx WHO risk: low risk or
0.565
0.564
0.564
0.539
0.568
0.531
lower risk computed via DPD
Post-tx WHO risk: moderate risk or
0.555
0.554
0.550
0.546
0.541
0.523
lower risk computed via DDD
Post-tx WHO risk: moderate risk or
0.548
0.547
0.535
0.543
0.543
0.520
lower risk computed via MXD
Post-tx WHO risk: moderate risk or
0.577
0.575
0.560
0.543
0.568
0.554
lower risk computed via DPD
Post-tx Composite clinical
0.534
0.534
0.511
0.539
0.530
0.516
Outcome: Abstinent
Post-tx Composite clinical
Outcome: Moderate drinking or
0.563
0.562
0.538
0.553
0.552
0.543
abstinent
Post-tx Composite clinical
Outcome: Heavy drinking OR
0.569
0.567
0.553
0.534
0.576
0.550
problems, moderate drinking, or
abstinent
1 or more risk level change in
0.562
0.561
0.564
0.541
0.548
0.540
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WHO risk level baseline to post-tx
(computed via DDD)
1 or more risk level change in
WHO risk level baseline to post-tx
(computed via DPD)
2 or more risk level change in
WHO risk level baseline to post-tx
(computed via DDD)
2 or more risk level change in
WHO risk level baseline to post-tx
(computed via DPD)
12mo Abstinence
12mo Heavy Drinking
12mo WHO risk: low risk or lower
risk computed via DDD
12mo WHO risk: low risk or lower
risk computed via MXD
12mo WHO risk: low risk or lower
risk computed via DPD
12mo WHO risk: moderate risk or
lower risk computed via DDD
12mo WHO risk: moderate risk or
lower risk computed via MXD
12mo WHO risk: moderate risk or
lower risk computed via DPD
12mo Composite clinical Outcome:
Abstinent
12mo Composite clinical Outcome:
Moderate drinking or abstinent
12mo Composite clinical Outcome:
Heavy drinking OR problems,
moderate drinking, or abstinent

0.546

0.548

0.547

0.555

0.523

0.524

0.536

0.537

0.539

0.532

0.533

0.515

0.503

0.504

0.510

0.516

0.492

0.491

0.499
0.518

0.501
0.521

0.501
0.530

0.501
0.513

0.507
0.528

0.490
0.495

0.511

0.513

0.517

0.510

0.518

0.493

0.509

0.511

0.512

0.510

0.514

0.496

0.530

0.532

0.545

0.524

0.534

0.501

0.532

0.533

0.540

0.527

0.529

0.503

0.520

0.522

0.528

0.517

0.528

0.495

0.547

0.548

0.545

0.537

0.548

0.514

0.506

0.509

0.512

0.509

0.505

0.497

0.534

0.535

0.536

0.525

0.541

0.512

0.559

0.561

0.552

0.532

0.563

0.539
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Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 16
Receiver operating characteristic curve area under the curve (AUC) results for the Health Survey (SF-12) for detecting/discriminating
post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
SF-12 total score
Physical Factor
Psychological Factor
Post-tx Abstinence
0.624
0.578
0.637
Post-tx Heavy Drinking
0.671
0.610
0.686
Post-tx WHO risk: low risk or lower risk computed via
0.654
0.598
0.667
DDD
Post-tx WHO risk: low risk or lower risk computed via
0.646
0.586
0.663
MXD
Post-tx WHO risk: low risk or lower risk computed via
0.701
0.652
0.695
DPD
Post-tx WHO risk: moderate risk or lower risk computed
0.677
0.632
0.681
via DDD
Post-tx WHO risk: moderate risk or lower risk computed
0.672
0.615
0.684
via MXD
Post-tx WHO risk: moderate risk or lower risk computed
0.724
0.672
0.724
via DPD
Post-tx Composite clinical Outcome: Abstinent
0.633
0.593
0.641
Post-tx Composite clinical Outcome: Moderate drinking
or abstinent
0.754
0.707
0.745
Post-tx Composite clinical Outcome: Heavy drinking OR
problems, moderate drinking, or abstinent
0.836
0.766
0.840
1 or more risk level change in WHO risk level baseline to
0.601
0.574
0.611
post-tx (computed via DDD)
1 or more risk level change in WHO risk level baseline to
0.577
0.522
0.603
post-tx (computed via DPD)
2 or more risk level change in WHO risk level baseline to
0.601
0.560
0.616
post-tx (computed via DDD)
2 or more risk level change in WHO risk level baseline to
0.578
0.529
0.600
post-tx (computed via DPD)
12mo Abstinence
0.548
0.518
0.561
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12mo Heavy Drinking
0.595
0.562
0.604
12mo WHO risk: low risk or lower risk computed via
0.599
0.562
0.608
DDD
12mo WHO risk: low risk or lower risk computed via
0.592
0.557
0.601
MXD
12mo WHO risk: low risk or lower risk computed via
0.630
0.586
0.637
DPD
12mo WHO risk: moderate risk or lower risk computed
0.609
0.580
0.614
via DDD
12mo WHO risk: moderate risk or lower risk computed
0.603
0.570
0.608
via MXD
12mo WHO risk: moderate risk or lower risk computed
0.632
0.593
0.635
via DPD
12mo Composite clinical Outcome: Abstinent
0.561
0.540
0.565
12mo Composite clinical Outcome: Moderate drinking or
abstinent
0.632
0.590
0.636
12mo Composite clinical Outcome: Heavy drinking OR
problems, moderate drinking, or abstinent
0.681
0.627
0.693
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 17
Receiver operating characteristic curve area under the curve (AUC) results for the Psychosocial Functioning Inventory (PFI) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
Subjective
Overall Social
Housemate/
Role
Role
PFI total score
Roommate
Performance
Performance
Factor
Factor
Factor
Post-tx Abstinence
0.608
0.545
0.575
0.575
Post-tx Heavy Drinking
0.646
0.599
0.617
0.604
Post-tx WHO risk: low risk or lower risk computed via
0.642
0.588
0.608
0.613
DDD
Post-tx WHO risk: low risk or lower risk computed via
0.631
0.571
0.593
0.601
MXD
Post-tx WHO risk: low risk or lower risk computed via
0.671
0.630
0.625
0.660
DPD
Post-tx WHO risk: moderate risk or lower risk
0.651
0.610
0.626
0.611
computed via DDD
Post-tx WHO risk: moderate risk or lower risk
0.644
0.596
0.614
0.602
computed via MXD
Post-tx WHO risk: moderate risk or lower risk
0.700
0.644
0.663
0.658
computed via DPD
Post-tx Composite clinical Outcome: Abstinent
0.611
0.559
0.579
0.573
Post-tx Composite clinical Outcome: Moderate
0.648
0.611
0.599
0.614
drinking or abstinent
Post-tx Composite clinical Outcome: Heavy drinking
0.665
0.626
0.637
0.613
OR problems, moderate drinking, or abstinent
1 or more risk level change in WHO risk level baseline
0.595
0.598
0.580
0.587
to post-tx (computed via DDD)
1 or more risk level change in WHO risk level baseline
0.574
0.556
0.552
0.552
to post-tx (computed via DPD)
2 or more risk level change in WHO risk level baseline
0.584
0.577
0.571
0.571
to post-tx (computed via DDD)
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2 or more risk level change in WHO risk level baseline
0.538
0.522
0.520
0.537
to post-tx (computed via DPD)
12mo Abstinence
0.553
0.517
0.531
0.538
12mo Heavy Drinking
0.591
0.552
0.551
0.577
12mo WHO risk: low risk or lower risk computed via
0.586
0.546
0.549
0.568
DDD
12mo WHO risk: low risk or lower risk computed via
0.574
0.532
0.537
0.554
MXD
12mo WHO risk: low risk or lower risk computed via
0.581
0.554
0.540
0.569
DPD
12mo WHO risk: moderate risk or lower risk computed
0.596
0.568
0.559
0.579
via DDD
12mo WHO risk: moderate risk or lower risk computed
0.589
0.554
0.548
0.572
via MXD
12mo WHO risk: moderate risk or lower risk computed
0.574
0.576
0.542
0.563
via DPD
12mo Composite clinical Outcome: Abstinent
0.565
0.523
0.538
0.545
12mo Composite clinical Outcome: Moderate drinking
0.600
0.573
0.583
0.571
or abstinent
12mo Composite clinical Outcome: Heavy drinking OR
0.597
0.582
0.585
0.564
problems, moderate drinking, or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 18
Receiver operating characteristic curve area under the curve (AUC) results for the Alcohol Abstinence Self-Efficacy (AASE) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in the COMBINE Study
COMBINE
AASE
AASE
Negative
Social
Physical
Urge
AASE total Confidence Temptation
Affect
Factor
Factor
Factor
score
Subscale
Subscale
Factor
Post-tx Abstinence
0.583
0.793
0.790
0.561
0.507
0.592
0.574
Post-tx Heavy Drinking
0.592
0.804
0.790
0.569
0.531
0.599
0.576
Post-tx WHO risk: low risk or
0.589
0.796
0.788
0.568
0.521
0.588
0.578
lower risk computed via DDD
Post-tx WHO risk: low risk or
0.593
0.808
0.804
0.566
0.513
0.592
0.587
lower risk computed via MXD
Post-tx WHO risk: low risk or
0.593
0.814
0.799
0.571
0.554
0.585
0.580
lower risk computed via DPD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.601
0.790
0.766
0.574
0.551
0.600
0.580
DDD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.590
0.796
0.784
0.566
0.521
0.597
0.577
MXD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.625
0.845
0.810
0.615
0.580
0.590
0.601
DPD
Post-tx Composite clinical
0.579
0.787
0.790
0.570
0.498
0.587
0.568
Outcome: Abstinent
Post-tx Composite clinical
Outcome: Moderate drinking
0.593
0.867
0.858
0.569
0.554
0.592
0.572
or abstinent
Post-tx Composite clinical
Outcome: Heavy drinking OR
0.620
0.879
0.852
0.618
0.564
0.621
0.578
problems, moderate drinking,
or abstinent
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1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
12mo Abstinence
12mo Heavy Drinking
12mo WHO risk: low risk or
lower risk computed via DDD
12mo WHO risk: low risk or
lower risk computed via MXD
12mo WHO risk: low risk or
lower risk computed via DPD
12mo WHO risk: moderate
risk or lower risk computed via
DDD
12mo WHO risk: moderate
risk or lower risk computed via
MXD
12mo WHO risk: moderate
risk or lower risk computed via
DPD
12mo Composite clinical
Outcome: Abstinent
12mo Composite clinical

0.554

0.674

0.669

0.545

0.530

0.548

0.547

0.547

0.699

0.698

0.535

0.535

0.537

0.547

0.546

0.711

0.719

0.527

0.504

0.553

0.537

0.544

0.691

0.688

0.527

0.509

0.550

0.542

0.516
0.542

0.664
0.687

0.690
0.701

0.509
0.529

0.459
0.478

0.532
0.543

0.521
0.541

0.532

0.685

0.709

0.510

0.474

0.538

0.538

0.523

0.692

0.717

0.505

0.465

0.534

0.531

0.557

0.698

0.707

0.531

0.509

0.543

0.554

0.548

0.683

0.692

0.523

0.500

0.543

0.547

0.537

0.683

0.700

0.515

0.476

0.541

0.540

0.549

0.715

0.724

0.526

0.496

0.540

0.547

0.550

0.698

0.708

0.535

0.480

0.562

0.555

0.577

0.732

0.734
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0.558

0.507

0.568

0.576

Outcome: Moderate drinking
or abstinent
12mo Composite clinical
Outcome: Heavy drinking OR
0.597
0.729
0.723
0.572
0.541
0.588
0.580
problems, moderate drinking,
or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 19
Receiver operating characteristic curve area under the curve (AUC) results for the Alcohol Abstinence Self-Efficacy (AASE) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in Project MATCH
MATCH
AASE
AASE
Negative
Social
Physical
Urge
AASE total Confidence Temptation
Affect
Factor
Factor
Factor
score
Subscale
Subscale
Factor
Post-tx Abstinence
0.573
0.720
0.703
0.527
0.533
0.576
0.578
Post-tx Heavy Drinking
0.554
0.726
0.735
0.501
0.519
0.554
0.554
Post-tx WHO risk: low risk or
0.563
0.726
0.722
0.507
0.529
0.564
0.564
lower risk computed via DDD
Post-tx WHO risk: low risk or
0.562
0.725
0.721
0.512
0.523
0.566
0.567
lower risk computed via MXD
Post-tx WHO risk: low risk or
0.532
0.730
0.758
0.471
0.528
0.538
0.544
lower risk computed via DPD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.539
0.716
0.735
0.485
0.512
0.543
0.541
DDD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.553
0.726
0.735
0.502
0.517
0.553
0.554
MXD
Post-tx WHO risk: moderate
risk or lower risk computed via
0.523
0.733
0.767
0.475
0.519
0.531
0.533
DPD
Post-tx Composite clinical
0.550
0.701
0.702
0.511
0.524
0.560
0.550
Outcome: Abstinent
Post-tx Composite clinical
Outcome: Moderate drinking
0.542
0.720
0.735
0.492
0.516
0.563
0.542
or abstinent
Post-tx Composite clinical
Outcome: Heavy drinking OR
0.540
0.717
0.735
0.483
0.514
0.550
0.542
problems, moderate drinking,
or abstinent
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1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
1 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DDD)
2 or more risk level change in
WHO risk level baseline to
post-tx (computed via DPD)
12mo Abstinence
12mo Heavy Drinking
12mo WHO risk: low risk or
lower risk computed via DDD
12mo WHO risk: low risk or
lower risk computed via MXD
12mo WHO risk: low risk or
lower risk computed via DPD
12mo WHO risk: moderate
risk or lower risk computed via
DDD
12mo WHO risk: moderate
risk or lower risk computed via
MXD
12mo WHO risk: moderate
risk or lower risk computed via
DPD
12mo Composite clinical
Outcome: Abstinent
12mo Composite clinical

0.534

0.668

0.626

0.502

0.517

0.537

0.534

0.545

0.628

0.565

0.515

0.529

0.555

0.534

0.543

0.685

0.537

0.503

0.515

0.552

0.544

0.536

0.611

0.572

0.520

0.512

0.547

0.529

0.555
0.536

0.666
0.667

0.655
0.674

0.524
0.499

0.512
0.511

0.568
0.545

0.556
0.534

0.543

0.681

0.681

0.505

0.509

0.552

0.542

0.544

0.672

0.670

0.510

0.508

0.556

0.546

0.540

0.689

0.700

0.497

0.517

0.551

0.544

0.534

0.682

0.694

0.494

0.516

0.544

0.528

0.538

0.675

0.681

0.502

0.511

0.547

0.535

0.522

0.672

0.700

0.504

0.514

0.524

0.513

0.556

0.689

0.679

0.520

0.519

0.563

0.550

0.537

0.690

0.712
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0.493

0.504

0.553

0.531

Outcome: Moderate drinking
or abstinent
12mo Composite clinical
Outcome: Heavy drinking OR
0.503
0.649
0.696
0.465
0.501
0.516
0.500
problems, moderate drinking,
or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 20
Receiver operating characteristic curve area under the curve (AUC) results for the Addiction Severity Index (ASI) for
detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes
ASI total score
Post-tx Abstinence
0.551
Post-tx Heavy Drinking
0.568
Post-tx WHO risk: low risk or lower risk computed
0.569
via DDD
Post-tx WHO risk: low risk or lower risk computed
0.559
via MXD
Post-tx WHO risk: low risk or lower risk computed
0.599
via DPD
Post-tx WHO risk: moderate risk or lower risk
0.583
computed via DDD
Post-tx WHO risk: moderate risk or lower risk
0.568
computed via MXD
Post-tx WHO risk: moderate risk or lower risk
0.612
computed via DPD
Post-tx Composite clinical Outcome: Abstinent
0.538
Post-tx Composite clinical Outcome: Moderate
0.562
drinking or abstinent
Post-tx Composite clinical Outcome: Heavy
drinking OR problems, moderate drinking, or
0.573
abstinent
1 or more risk level change in WHO risk level
0.528
baseline to post-tx (computed via DDD)
1 or more risk level change in WHO risk level
0.514
baseline to post-tx (computed via DPD)
2 or more risk level change in WHO risk level
0.510
baseline to post-tx (computed via DDD)
2 or more risk level change in WHO risk level
0.494
baseline to post-tx (computed via DPD)
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12mo Abstinence
0.504
12mo Heavy Drinking
0.515
12mo WHO risk: low risk or lower risk computed
0.514
via DDD
12mo WHO risk: low risk or lower risk computed
0.508
via MXD
12mo WHO risk: low risk or lower risk computed
0.523
via DPD
12mo WHO risk: moderate risk or lower risk
0.525
computed via DDD
12mo WHO risk: moderate risk or lower risk
0.515
computed via MXD
12mo WHO risk: moderate risk or lower risk
0.492
computed via DPD
12mo Composite clinical Outcome: Abstinent
0.511
12mo Composite clinical Outcome: Moderate
0.535
drinking or abstinent
12mo Composite clinical Outcome: Heavy drinking
0.544
OR problems, moderate drinking, or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Table 21
Receiver operating characteristic curve area under the curve (AUC) results for percent days abstinent (PDA) and percent heavy
drinking days (PHDD) for detecting/discriminating post-treatment (post-tx) and 12-month follow-up (12mo) consumption outcomes in
the COMBINE Study and Project MATCH
COMBINE
MATCH
COMBINE PDA
MATCH PDA
PHDD
PHDD
Post-tx Abstinence
0.880
0.897
Post-tx Heavy Drinking
0.900
0.955
Post-tx WHO risk: low risk or lower risk computed via
0.922
0.937
0.962
0.945
DDD
Post-tx WHO risk: low risk or lower risk computed via
0.962
0.919
0.979
0.944
MXD
Post-tx WHO risk: low risk or lower risk computed via
0.960
0.955
0.971
0.983
DPD
Post-tx WHO risk: moderate risk or lower risk
0.849
0.970
0.929
0.987
computed via DDD
Post-tx WHO risk: moderate risk or lower risk
0.909
0.986
0.958
0.994
computed via MXD
Post-tx WHO risk: moderate risk or lower risk
0.954
0.988
0.970
0.990
computed via DPD
Post-tx Composite clinical Outcome: Abstinent
0.975
0.846
0.882
0.803
Post-tx Composite clinical Outcome: Moderate
0.946
0.960
0.872
0.844
drinking or abstinent
Post-tx Composite clinical Outcome: Heavy drinking
0.876
0.902
0.834
0.849
OR problems, moderate drinking, or abstinent
1 or more risk level change in WHO risk level baseline
0.670
0.726
0.698
0.672
to post-tx (computed via DDD)
1 or more risk level change in WHO risk level baseline
0.724
0.731
0.682
0.611
to post-tx (computed via DPD)
2 or more risk level change in WHO risk level baseline
0.757
0.753
0.745
0.679
to post-tx (computed via DDD)
2 or more risk level change in WHO risk level baseline
0.745
0.732
0.666
0.610
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to post-tx (computed via DPD)
12mo Abstinence
0.806
0.682
0.724
0.668
12mo Heavy Drinking
0.736
0.740
0.721
0.703
12mo WHO risk: low risk or lower risk computed via
0.753
0.719
0.726
0.695
DDD
12mo WHO risk: low risk or lower risk computed via
0.773
0.709
0.728
0.686
MXD
12mo WHO risk: low risk or lower risk computed via
0.798
0.768
0.748
0.724
DPD
12mo WHO risk: moderate risk or lower risk computed
0.719
0.742
0.711
0.709
via DDD
12mo WHO risk: moderate risk or lower risk computed
0.737
0.734
0.723
0.700
via MXD
12mo WHO risk: moderate risk or lower risk computed
0.773
0.778
0.733
0.727
via DPD
12mo Composite clinical Outcome: Abstinent
0.773
0.686
0.743
0.688
12mo Composite clinical Outcome: Moderate drinking
0.787
0.756
0.754
0.724
or abstinent
12mo Composite clinical Outcome: Heavy drinking OR
0.716
0.723
0.694
0.683
problems, moderate drinking, or abstinent
Note: DDD = drinks per drinking day; MXD = maximum number of drinks consumed in the 90-day window; DPD = drinks per day in
the assessment window (averaged across drinking and abstinent days). AUC > 0.650 have been bolded and underlined for improved
readability.
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Appendix A
Individual Item Receiver Operating Characteristic Curve Results
Brief Symptom Inventory. Since ROC curve analyses for the BSI total and subscale
score yielded AUC’s > 0.650, ROC curve analyses were conducted for individual items. Items 1
(nervousness or shakiness; Anxiety subscale item), 15 (feeling blocked in getting things done;
Obsessive-Compulsive subscale item), and 17 (feeling blue; Depression subscale item)
adequately detected 4 of 15 post-treatment outcomes: WHO low or lower risk level (calculated
via DPD; AUC = 0.687, 0.687, 0.674), WHO moderate or lower risk level (calculated via DPD;
AUC = 0.720, 0.684, 0.704), composite clinical outcome of moderate or lower risk (AUC =
0.717, 0.686, 0.706), and composite clinical outcome of heavy or lower risk (AUC = 0.772,
0.767, 0.786). Items 6 (annoyed or irritated; Hostility subscale item), 18 (lack of interest;
Depression subscale item), 19 (feeling fearful; Anxiety subscale item), 36 (trouble concentrating;
Obsessive-Compulsive subscale item), and 38 (tense/keyed up; Anxiety subscale item) all
adequately detected 3 of 15 post-treatment outcomes: WHO moderate or lower risk level
(calculated via DPD; AUC = 0.683, 0.660, 0.656, 0.672, 0.669), composite clinical outcome of
moderate or lower risk (AUC = 0.677, 0.678, 0.650, 0.670, 0.670), and composite clinical
outcome of heavy or lower risk (AUC = 0.768, 0.760, 0.697, 0.751, 0.738). In addition to the
above items, post-treatment composite clinical outcome of moderate or lower risk and composite
clinical outcome of heavy or lower risk were also both adequately detected by item 5 (trouble
remembering; Obsessive-Compulsive subscale item; AUC’s = 0.667, 0.678), item14 (feeling
lonely; Psychoticism subscale item; AUC’s = 0.653, 0.710), item 16 (feeling lonely; Depression
subscale item; AUC’s = 0.686, 0.763), item 35 (hopeless; Depression subscale item; AUC’s =
0.674, 0.758), item 50 (worthlessness; Depression subscale item; AUC’s = 0.659, 0.724), and
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items 52 (guilt; Interpersonal Sensitivity subscale item; AUC’s = 0.683, 0.737) and 53 (ideas
something is wrong with you; Psychoticism subscale item; AUC’s = 0.677, 0.747). Post
treatment composite clinical outcome of heavy or lower risk was also adequately detected by 15
other items, which made it the most readily detected post-treatment consumption outcome.
Moreover, 12-month follow-up composite clinical outcome of heavy or lower risk was the only
12-month follow-up consumption outcome that was adequately detected by any BSI individual
items and it was adequately detected by 7 items: 6 (annoyed or irritated; Hostility subscale item),
15 (feeling blocked in getting things done; Obsessive-Compulsive subscale item), 16 (feeling
lonely; Depression subscale item), 17 (feeling blue; Depression subscale item), 18 (lack of
interest; Depression subscale item), 52 (guilt; Interpersonal Sensitivity subscale item), and 53
(ideas something is wrong with you; Psychoticism subscale item).
World Health Organization Quality of Life, Brief Version. Since ROC curve analyses
for the week 26 WHOQOL-BREF subscales yielded adequate detection of 12-month
consumption outcomes (AUC’s > 0.650), analyses were conducted for individual items of the
week 26 WHOQOL-BREF for detecting 12-month consumption outcomes. The 12-month
composite clinical outcome of heavy or lower risk was adequately detected by 8 of the individual
items: item 5 (enjoy life; Psychological Health subscale item; AUC = 0.675), item 6 (life is
meaningful; Psychological Health subscale item; AUC = 0.665), item 7 (able to concentrate;
Psychological Health subscale item; AUC = 0.655), item 16 (sleep satisfaction; Physical Health
subscale item; AUC = 0.661), item 17 (daily activities; Physical Health subscale item; AUC =
0.696), item 18 (capacity for work; Physical Health subscale item; AUC = 0.650), item 20
(personal relationships; Social subscale item; AUC = 0.673), and item 22 (friend support; Social
subscale item; AUC = 0.654).
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Beck Depression Inventory. Since the BDI subscales adequately detected some posttreatment consumption outcomes, ROC curve analyses were conducted for individual items’
ability to detect post-treatment outcomes. The outcomes that were adequately detected were
WHO low or lower risk level (calculated via DPD; WLLP) and WHO moderate or lower risk
level (calculated via DPD; WMLP). Items 4 (satisfaction in activities) and 7 (self-dislike) were
able to adequately detect both of these outcomes: WLLP (AUC’s = 0.670, 0.671) and WMLP
(AUC’s = 0.674, 0.683). Item 15 (work ability) was only able to adequately detect post-treatment
WLLP (AUC = 0.650). Items 3 (personal failure), 5 (guilt), and 16 (sleep disturbance) were all
able to adequately detect post-treatment WMLP (AUC’s = 0.664, 0.661, 0.660).
Obsessive-Compulsive Drinking Scale. Given how well each sub-factor of the OCDS
did in ROC curve analyses, it is unsurprising individual items also performed well. Items 13
(drive to consume), and 14 (control over drinking) all adequately detected 15 of 15 posttreatment outcomes: AUC’s = 0.650-0.880, and 0.664-0.894. Item 12 (effort to resist drinking)
adequately detected 13 of 15 post-treatment outcomes: AUC’s = 0.624-0.845. Items 5 (effort to
resist thoughts), 6 (success in stopping thoughts), and 11 (anxiety over being prevented from
drinking) each adequately detected 12 of 15 post-treatment outcomes: AUC’s = 0.610-0.848,
0.635-0.848, 0.640-0.867). Items 1 (time thinking) and 4 (distress of thoughts) each adequately
detected 11 of 15 whereas item 10 (social functioning interference) adequately detected 10 of 15
post-treatment outcomes: AUC’s = 0.590-0.787, 0.574-0.806 and 0.598-0.853. Item 9 (work
functioning interference) adequately detected 8 of 15 post-treatment outcomes (AUC’s = 0.5840.811) and items 2 (thought frequency) and 3 (thought interference with social or work
functioning) each adequately detected 3 of 15 post-treatment outcomes: AUC’s = 0.576-0.718,
0.556-0.789. For 12-month follow-up outcomes, items 7 and 8 adequately detected 11 of 11
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outcomes (AUC’s = 0.672-0.737, 0.661-0.740); items 13 and 14 adequately detected 9 of 11
outcomes (AUC’s = 0.644-0.696, 0.647-0.704). Items 6, 11, and 12 each adequately detected 8
of 11 outcomes: AUC’s = 0.632-0.690, 0.642-0.698, and 0.639-0.690. Item 5 adequately
detected 2 of 11 12-month outcomes (AUC’s = 0.608-0.678) and items 1 and 4 adequately
detected 1 of 11 12-month outcomes: AUC’s = 0.602-0.668, 0.573-0.667. Post-treatment
outcomes of composite clinical outcome of heavy or lower risk and 2+ change in WHO risk level
since baseline (calculated via DPD) were the most and least detectable consumption outcomes
for 9 of the 14 of individual items. For items that were able to adequately detect at least one 12month outcome (AUC > 0.650), composite clinical outcome of moderate or lower risk and
composite clinical outcome of heavy or lower risk yielded the highest AUC’s; abstinence and
WHO moderate or lower risk (calculated via MXD) yielded the lowest AUC’s.
Drinker Inventory of Consequences. The 3 factors that were upheld via CFA and
measurement invariance testing for the DrInC in both COMBINE and MATCH yielded high
AUC values in ROC curve analyses. Therefore, individual item ROC curve analyses were
conducted for COMBINE and MATCH DrInC data.
In COMBINE, several individual items were able to adequately detect post-treatment
outcomes. Items 1 and 2 (hangover, felt bad about self) adequately detected all post-treatment
outcomes (AUC’s = 0.664-0.880, 0.651-0.870); item 12 (unhappy due to drinking) adequately
detected 14 of 15 post-treatment outcomes (AUC’s = 0.640-0.898). Item 16 (guilt/ashamed;
AUC’s = 0.630-0.881) adequately detected 13 of 15 post-treatment outcomes. Several individual
items were able to adequately detect 11 of 15 post-treatment outcomes: item 4 (family/friends
worried/complained; AUC’s = 0.602-0.805), item 8 (sleep disturbances; AUC’s = 0.578-0.833),
item 13 (eating disturbances; AUC’s = 0.597-0.888), item 18 (personality worsened; AUC’s =
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0.587-0.794), item 37 (undesired life; AUC’s = 0.607-0.883), and item 38 (personal growth
interference; AUC’s = 0.619-0.895). Item 28 (smoked more tobacco) adequately detected 10 of
15 post-treatment outcomes (AUC’s = 0.589-0.742); item 17 (said/done embarrassing things)
adequately detected 9 of 15 post-treatment outcomes (AUC’s = 0.591-0.804). Item 40 (spent too
much money) adequately detected 8 out of 15 post-treatment outcomes (AUC’s = 0.576-0.821).
Many items adequately detected 7 out of 15 post-treatment outcomes: item 14 (failed
expectations; AUC’s = 0.555-0.831), item 24 (physical health harmed; AUC’s = .593-0.838),
item 30 (hurt family; AUC’s = 0.560-0.784), item 34 (lost interest; AUC’s = 0.576-0.823), and
item 36 (spiritual/moral life harmed; AUC’s = 0.583-0.794). Items 22 (impulsivity) and 39
(damaged social life) adequately detected 5 of 15 post-treatment outcomes (AUC’s = 0.5690.818, 0.555-0.794). Four items adequately detected 4 of 15 post-treatment outcomes: item 6
(work quality suffered; AUC’s = 0.582-0.801), item 9 (driven after 3+ drinks; AUC’s = 0.5940.744), item 29 (physical appearance harmed; AUC’s = 0.567-0.842), and item 33 (sex life
suffered; AUC’s = 0.569-0.776). Six items each adequately detected 3 of 15 post-treatment
outcomes: item 19 (foolish risks; AUC’s = 0.555-0.777), item 21 (said cruel things; AUC’s =
0.562-0.710), item 26 (money problems; AUC’s = 0.564-0.774), item 27 (marriage/love
relationship harmed; AUC’s = 0.559-0.717), item 31 (friendship damaged; AUC’s = 0.5570.751), and item 32 (overweight; AUC’s = 0.583-0.708). Item 20 (trouble; AUC’s = 0.5270.677) adequately detected 2 of 15 post-treatment outcomes; items 3 (missed school/work), item
7 (parenting ability), and 11 (vomited) each adequately detected 1 of 15 post-treatment outcomes
(AUC’s = 0.535-0.716, 0.535-0.684, 0.522-0.676). Items 10 (other drug use), 23 (physical fight),
and 41 through 50 (arrested for DWI, trouble with the law, lost marriage/love relationship,
suspended/fired, lost a friend, had an accident, been physically hurt, injured someone else, and
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broken things) all failed to detect any post-treatment outcomes (0 out of 15 outcomes; AUC’s <
0.650).
In COMBINE, some individual items of the DrInC also adequately detected 12-month
follow-up outcomes. Item 1 (hangover) adequately detected all 11 out of 11 12-month outcomes
(AUC’s = 0.663-0.698); item 2 (felt bad about self) adequately detected 10 of 11 12-month
outcomes (AUC’s = 0.639-0.713). Item 16 (guilt/ashamed) adequately detected 9 of 11 12-month
outcomes (AUC’s = 0.638-0.714); item 12 (unhappy due to drinking) adequately detected 6 of 11
12-month outcomes (AUC’s = 0.629-0.707). These findings are consistent with the ability of
these items to detect the majority of post-treatment outcomes. Additionally, item 38 (personal
growth interference) adequately detected 2 of 11 12-month outcomes (AUC’s = 0.559-0.706) and
several items adequately detected 1 of 11 12-month outcomes: item 8 (sleep disturbances), 13
(eating disturbances), 18 (personality worsened), 24 (physical health harmed), 29 (physical
appearance harmed), 30 (hurt family), 34 (lost interest), 36 (spiritual/moral life harmed), 37
(undesired life), and 40 (spent too much money).
In MATCH, several individual items were able to detect any post-treatment outcomes.
Item 1 (hangovers) adequately detected 9 out of the 11 post-treatment outcome tested (changes in
WHO risk since baseline were not analyzed due to the null findings for total DrInC and
individual factors for detecting those outcomes adequately; AUC’s = 0.596-0.733). Item 13
(eating disturbances) adequately detected 7 of 11 post-treatment outcomes (AUC’s = 0.5840.768). Items 12 (unhappy due to drinking) and 17(said/done embarrassing things) adequately
detected 6 of 11 post-treatment outcomes (AUC’s = 0.598-0.774, 0.575-0.771). Several items
were able to adequately detect 4 of the 11 post-treatment outcomes examined: item 2 (felt bad
about self ; AUC’s = 0.572-0.746), item 4 (family/friends worried/complained; AUC’s = 0.566125

0.757), item 6 (work quality suffered; AUC’s = 0.548-0.685), item 8 (sleep disturbances; AUC’s
= 0.521-0.719), item 14 (failed expectations; AUC’s = 0.550-0.757), item 16 (guilt/ashamed;
AUC’s = 0.568-0.740), item 18 (personality worsened; AUC’s = 0.540-0.784), item 21 (said
cruel things; AUC’s = 0.571-0.745), item 24 (physical health harmed; AUC’s = .563-0.755),
item 26 (money problems; AUC’s = 0.551-0.733), item 29 (physical appearance harmed; AUC’s
= 0.546-0.771), item 30 (hurt family; AUC’s = 0.551-0.772), item 34 (lost interest; AUC’s =
0.535-0.753), item 36 (spiritual/moral life harmed; AUC’s = 0.518-0.719), item 37 (undesired
life; AUC’s = 0.561-0.815), and item 38 (personal growth interference; AUC’s = 0.563-0.817),
and item 40 (spent too much money; AUC’s = 0.581-0.778). Five individual items each
adequately detected 3 of 11 post-treatment outcomes that were analyzed: item 9 (driven after 3+
drinks; AUC’s = 0.582-0.701), item 19 (foolish risks; AUC’s = 0.548-0.738), item 27
(marriage/love relationship harmed; AUC’s = 0.542-0.740), item 31 (friendship damaged;
AUC’s = 0.539-0.723), and item 39 (damaged social life; AUC’s = 0.509-0.752). Five items also
detected only 2 of the 11 analyzed post-treatment items: item 20 (trouble; AUC’s = 0.540-0.675),
item 22 (impulsivity; AUC’s = 0.540-0.727), item 28 (smoked more tobacco; AUC’s = 0.5400.721), and items 32 and 33 (overweight, AUC’s = 0.566-0.663; sex life suffered, AUC’s =
0.513-0.687). Item 7 (parenting ability) was able to adequately detect 1 of the 11 examined posttreatment outcomes (AUC’s = 0.537-0.657). All other items failed to adequately detect (AUC’s
< 0.650) any post-treatment consumption outcomes. In MATCH, several individual items on the
DrInC were most able to detect post-treatment composite clinical outcome of moderate or lower
risk and were poorest at detecting post-treatment abstinence.
Health Survey (SF-12). Since some of the post-treatment outcomes were adequately
detected by each of the factors, select ROC curve analyses were conducted for individual items
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based on which consumption outcomes were adequately detected by each item’s respective
factor. Item 6A (felt calm or peaceful) had the highest AUC values and adequately detected 8 out
of 9 post-treatment outcomes that were examined (AUC’s = 0.647-0.769). Item 6A was also the
only examined item that was able to adequately detect any 12-month follow-up outcome: AUC =
0.650 for 12-month follow-up composite clinical outcome of heavy or lower risk. Items 4B
(emotional interference with work/activities) and 6B (lots of energy) were able to adequately
detect 4 post-treatment outcomes with positive AUC’s = 0.651-0.763 and 0.650-0.775. Items 1
(general health), 4A (emotional interference with accomplishments)m and 6C
(downhearted/depressed) adequately detected 3 post-treatment outcomes: positive AUC’s =
0.656-0.773, 0.669-0.775, 0.654-0.715. Items 3A (physical health interference with
accomplishments) and 7 (physical/emotional interference with social activities) adequately
detected 2 post-treatment outcomes: positive AUC’s = 0.670-0.684, 0.650-0.713. Items 2A
(health limit moderate activities), 2B (health limit climbing stairs), 3B (physical health limits
work/activities times), and 5 (pain interference with work) were unable to detect any of the posttreatment outcomes that were examined in the present study.
Psychosocial Functioning Inventory. Only the Social Role Performance and
Housemate/Roommate Role factors yielded some adequate AUC values in ROC curve analyses.
Accordingly, individual item ROC curve analyses were conducted only for items from these two
factors for consumption outcomes that were adequately detected from the larger factor subscale
scores (i.e., only certain post-treatment consumption outcomes, and none of the 12-month
follow-up consumption outcomes since AUC’s were all < 0.650 for every factor subscale score).
From individual item ROC curve analyses conducted based on positive Social Role Performance
and Housemate/Roommate Role factors ROC curve analyses, only 2 items adequately detected
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any consumption outcomes. Item 11 (spousal/mate overall role performance; Social Role
Performance factor) adequately detected WHO moderate or lower risk level (calculated via DPD;
AUC = 0.677) as did item 19 (housemate/roommate overall role performance, AUC = 0.658).
These two items were the only examined items that detected any post-treatment or 12-month
follow-up outcomes and each only adequately detected one consumption outcome (WHO
moderate or lower risk level (calculated via DPD).
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